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L Abstract 
The aim of this project is to identify potential target genes (NTG's) which may be 
regulated by N-myc in the cell line SK-N-SH which has no amplification of the 
oncogene N-myc. 
N-myc target genes were isolated using a modification of the protocol developed to 
identify p53 binding sites; this was done by generating a NTG library by isolating 
genomic DNA from SK-N-SH cells, digesting to completion with Sau3A, and 
mixing with nuclear extract from the same cell line. N-myc antibody was added 
and DNA-protein complexes immunoprecipitated to isolate DNA with N-Myc 
bound. DNA recovered from these precipitates was then cloned into pBluescript 
SK+. 400 clones were isolated, 4 of which were partially sequenced and compared 
to sequence data bases. 
The NTG clones showed substantial sequence identity to a number of potentially 
interesting genes, among them several implicated in tumour suppression, and the 
expression of cell surface markers. Their significance for neuroblastoma is 
discussed. 
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1. Introduction 
Cancer is a group of more than 100 different diseases. It occurs when cells 
become abnormal and keep dividing without control or order forming a mass of 
excess tissue called a tumour. 
Tumours can be benign (not cancer) or malignant (cancer). The cells in malignant 
tumours can invade and damage nearby tissues and organs. Cancer cells can also 
break away from a malignant tumour and travel through the bloodstream or the 
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Figure 1.1, The development of cancer. 
Cancer is not a new disease, as sometimes humans and fossil bones of dinosaurs 
show evidence of the disease. Its apparent increase may be due to the increased 
longevity of humans. 
Knowledge about the development of tumours is progressing, and new types o f 
treatments are expected soon. 
It is only in the past 50 years that generalised hypotheses about cancer have led to 
specific findings that shape the treatment people receive. 




Neuroblastoma occurs at a rate of about 1/100,000 per year, most often in babies, 
very young children (under the age of 15 years), and in the unborn in rare cases. It 
is slightly more common in white children than in black and slightly more common 
in boys than girls. About 75% of cases are diagnosed before the age of 5 years. 
Although most frequently presenting as a large abdominal mass, this tumour is 
metastasised in 70% of patients at diagnosis, and there has been little advance in 
survival over the last 20 years for advanced disease. 
The most common primary site is the adrenal gland (40%), pelvis (5%) and neck 
(5%) are the other sites seen. The tumours arise from neural crest cells which form 
part of the sympathetic nervous system. 
1.2. Stage explanation: 
Stagel. Localized resectable: The cancer is found only in the place where it started and 
can be removed by surgery. 
Stagell. Localized unresectable: The cancer is found only in the place where it started but 
it cannot be totally removed by surgery. 
Stagelll. Regional : The cancer has spread from where it started to the tissue around it or 
to the lymph nodes in the abdomen. 
StagelV. Disseminated : The cancer has spread to lymph nodes outside the abdomen or to 
the bone, liver, or other organs. 
StageV. The cancer is in the place where it began and has spread only to the liver, skin, 
and / or bone marrow. 
StageVI. Recurrent neuroblastoma means that the cancer has come back after it has been 
treated. 
1.3. Treatment options 
Treatment for Neuroblastoma depends on: the stage of the child's disease, the 
child's age and the general health. 
In general, four types of treatment are used: 
• Surgery. 
© Radiation therapy. 
• Chemotherapy. 
• Bone marrow transplantation (using high doses of chemotherapy with or 
without radiation therapy to destroy the cancer cells and putting bone marrow 
back into the bone. 
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1.4. Molecular Characteristics of Neuroblastoma Cells 
1.4.1. Decreased expression of the major histocompatibility complex class 1 
antigen MHC ( they are cell surface glycoproteins that are required for the 
recognition of target cells by cytotoxic T lymphocytes). This decrease is thought to 
correlate with high level of expression of the N-myc gene. 
1.4.2. Urinary Catecholamines 
At least 85-90% of tumours have increased levels of catecholamine in the serum 
and urine [dopa, dopamine, norepinephrine, normetanephrine, homovanillic acid 
(HVA), vanillylamaidlic acid (VMA)] . 
The levels are not a guide to prognosis but measurement of total 
catecholamines,(VMA) and (HVA) can be used as a marker of effective treatment 
i f initially elevated. 
Some evidence suggests that the ratio of V M A to H V A may correlate with 
prognosis in disseminated disease , the higher the ratio the better the prognosis. 
The presence of vanillyl acetic acid (VAA) in the urine may be associated with a 
poor prognosis as may be the elevation of urinary cystathionine levels. Plasma 
dopamine may be elevated but is rarely measured. 
I TYROSINE | 
Tyrosine hydroxylase I 
I DOPA I 
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Figure 1.2, Catecholamine Metabolism 
1.4.3. Deletion and loss of putative suppresser genes on lp and 14q 
The most characteristic cytogenetic abnormality in neuroblastoma is the deletion at 
the distal end of the short arm of chromosome 1 from lp 36.1 to lp 36.3 , and it is 
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thought that the p arm of chromosome 1 probably harbours a series of suppresser 
genes that play a key role in neuroblastoma differentiation. 
There is also recent evidence that a deletion or loss of the long arm of chromosome 
14 also accrues with increased frequency in neuroblastomas [1,2] and probably 
represents loss of another suppresser gene . 
Another allelic loss has been found involving 11 q and 13q in some studies, but not 
in others[l,2] so the significance of these findings is unclear. 
1.4.4. Expression of the nerve growth factor receptors 
As mentioned before, neuroblastoma is derived from the sympathoadrenal lineage 
of the neural crest. Neurotrophic factors and their receptors have been implicated 
in the pathogenesis of neuroblastoma. Neurotrophins are a family of related 
molecules that promote neuronal survival and differentiation in the central and 
peripheral nervous system, these includes nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4/5 
(NT-4/5) [3]. 
NGF, the first of the neurotrophins to be discovered, has been shown to be 
essential for survival and differentiation of neural crest-derived peripheral 
sympathetic and sensory neurones, as well as cholinergic neurones in the central 
nervous system [4]. 
Two (NGF) receptor sub-units, the high affinity NGF receptor with tyrosine kinase 
T R K A 
activity (PI40 ), and a transmemberane glycoprotein, the low affinity NGF 
receptor (P75 N G F R ) , are thought to be required for high affinity NGF binding, and 
probably for signal transduction [5,6], and that detectability of the NGF receptor 
T R K . A 
sub-unit PI 40 ), expressed at different levels by the majority of 
neuroblastoma's, was associated with lower stage of disease, lower age of patients, 
and was inversely related to N-myc amplification [7]. 
1.4.5. N-myc amplification and expression 
Amplification of cellular oncogenes is one of the major genetic alterations that 
appears to contribute to tumorigenesis [8,9], while most tumours show sporadic 
amplification of cellular oncogenes, human neuroblastoma tumours show frequent 
amplification of the N-myc gene which correlates with aggressive tumour growth. 
A study involving 64 tumours of patients not subjected to therapy revealed that 
amplification of N-myc gene was limited to stage I I I and IV tumours [10]. 
Amplification was discovered in approximately 50% of all stage I I I and IV 
tumours. This implies that amplification of N-myc is a late event in the 
development of neuroblastomas. 
The amplification sequence (N-myc) is found either on extrachromosomal double 
minutes (DMs) or on the homogenous staining regions (HSRs) on different 
10 
chromosomes in neuroblastoma cell lines, and the normal single-copy locus was 
mapped to the distal short arm of chromosome 2 band p23-24 [11,12]. 
Subsequent studies revealed amplification of N-myc also in small cell lung 
cancers, retinoblastoma, malignant gliomas and astrocytomas, also low expresion 
of N-Myc is detectable in neuroblastoma cells lacking amplification such as the 
human neuroblastoma line SK-N-SH or the murine neuroblastoma line Neuro2a, 
the SH-SY5Y cell line, and Gl -ME-N cell line. 
The process of gene amplification in general usually involves co-amplification of 
extensive regions of DNA that share a common origin but which become re-
arranged with subsequent amplification events [13]. 
Recently another gene DDX1, has been shown to be co-amplified with N-myc in 
two retinoblastoma cell lines [14], however rarely in neuroblastoma cell lines, and 
i f so limited to stage 4, 4s. 
DDX1 is a member of the DEAD box gene family, has eight highly conserved 
amino acid motif and maps to the chromosomal region 2p24, the same 
chromosomal band that N-myc maps to (2p-23-24). 
It is still unclear whether the DDX1 protein directly affects N-myc processing or 
it's stability or the rate of translation of the N-Myc protein. 
Another gene which has been shown to be co-amplified with N-myc in 
neuroblastoma cell lines is the ornithine decarboxylase (ODC1) gene which maps 
to chromosome 2p24-25, it co-amplifies with N-myc in one of six primary 
neuroblastomas [15]. 
As a result of N-myc amplification, elevated levels of the N-Myc protein are 
expressed. 
N-Myc is like other proteins of the MYC gene family, a short lived protein, located 
in the nucleus of the cell, phosphorylated by Casein Kinase I I (CKII) and binds 
DNA. It contains a carboxy-terminus, that has a nuclear localisation signal (N), a 
basic region (BR) responsible for DNA binding, helix-loop-helix (HLH) and a 
leucine zipper domain (Zip). 
N BR HI L H2Zip 
337 344 371 456 
N-myc 
Figure 1.3, Functional domains ofN-wyc 
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The HLH-Zip domain is responsible for the physical interaction with another HLH-
Zip protein, Max, this principal structure of the C-terminus is shared among all 
members of the myc family of proteins (C-,L-, and N-Myc). 
The MYC family of proteins are thought to be involved in transcription because of 
having both a carboxy-terminal basic-helix-loop-helix-zipper (bHLH-Z) domain, 
common to a large class of transcription factors [16], and an amino-terminal 
fragment which, for C-Myc has transactivating function when assayed in chimaeric 
constructs [17]. 
As mentioned before, C-, N - and L-Myc proteins heterodimerize in vitro and in 
vivo with the bHLH-Z protein Max. In vitro, Max homodimerizes but 
preferentially associates with Myc, which homodimerizes poorly [18]. 
The resulting Myc-Max heterodimer, binds the nucleotide sequence CACGTG with 
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Figure 1.4, A speculative model for interaction and regulation 
of BR-HLH-Zip proteins in neuroblastoma. 
It is thought that Max-Max and Myc-Max complexes have distinct transcriptional 
functions, thus the relative amounts of Max homodimers and Myc-Max 
hetrodimers may affect the transcriptional activity of a reporter gene containing 
promoter-proximal Myc-Max binding sites. 
Transcription from such a reporter gene is stimulated by Myc over expression and 
repressed by Max over expression, activation is dependent on N - and C- terminal 
regions of Myc, while repression is dependent on the Max DNA-binding domain. 
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Max and Myc differ in several important biochemical properties, Myc is a highly 
unstable protein, whose synthesis is rapidly induced upon cell cycle entry, and 
maintained at a constant level in proliferating cells. 
By contrast Max is highly stable and is expressed at equivalent levels in both 
resting and proliferating cells [21]. 
As Max seems to be in excess of Myc in vivo and Myc's short half-life is unaltered 
by dimerization with Max, the rate of Myc synthesis determines the ratio of Max-
Max to Myc-Max complexes. 
In continuously growing neuroblastoma cells, where N-ravc is overexpressed as the 
result of amplification, the presence of N-myc forces Max into abnormal amounts 
of N-Myc-Max heterodimeric complexes, which could perturb the fine tuned 
expression of unidentified genes or possibly genes involved in control of the cell 
cycle and differentiation, see figure 4. 
The p21- and p22 m a x are the major variants that are expressed in a wide variety of 
species and cell types, and probably the predominantly expressed forms of Max in 
neuroblastoma cells. 
Expression of Max proteins is not restricted to cells with high levels of N-Myc, but 
was also observed in neuroblastoma cells without detectable N-myc expression. 
Max also interacts with C-myc. The C-myc proto-oncogene is a key regulator of 
cell growth and differentiation, it is localized in the nucleus and can activate 
transcription when brought to DNA by heterologous DNA binding domains [22], it 
contains an activation domain in its amino terminus, the integrity of which is 
correlated with its ability to cause oncogenic transformation [23]. 
Max protein is expressed in all tissues in which C-myc is expressed, and in some, 
including the adult brain in which C-myc is not. 
Max-Max homodimers and C-myc-Max heterodimers bind tightly to the E-box 
CACGTG, and while DNA bound C-myc-Max hetrodimers activate transcription, 
Max-Max homodimers do not. This fact strengthened the hypothesis that 
transcription regulation is important to Myc function [24,25]. 
The interaction between Max and C-myc is dependent on the integrity of the C-
myc HLH-Zip domain, but not on the basic region or other sequences outside the 
domain. As for C-myc there is substantial evidence that the bHLH region and the 
adjacent leucine zipper motif are functionally important, deletions within these 
regions result in loss or alteration of transforming activity as well as reduction of 
the capacity to autoregulate endogenous Myc expression and to inhibit cell 
differentiation [26,27]. 
It is suggested that because most C-myc in vivo is associated with Max and C-
myc-Max heterodimers bind CACGTG sites more tightly than C-myc-C-myc 
homodimers, that one function of Max is to facilitate the binding of C-myc to these 
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sites, and the fact that N-Myc and L-Myc as well as C-Myc specifially associate 
with Max suggests that Max may also serve to integrate the functions of these 
three proteins that are differentially expressed during development, differentiation, 
and neoplasia. 
Max (but not Myc) also interacts with other HLH-Zip proteins, Mad and M x i l and 
may also probably contribute to transcriptional control in neuroblastoma Mad-Max 
and Mxil-Max hetrodimers bind efficiently to the Myc-Max E-box. Thus, (Mad / 
Max heterodimers formed during the differentiation of cells are thought to be more 
effective repressors than max homodimers because of their higher DNA binding 
activity). 
It is also thought that Mad-Max and Mxil-Max heterodimers inhibit Myc-Max 
transactivation by sequestering Max and therefore preventing formation of Myc-
Max heterodimers, and also by competing with Myc-Max heterodimers for 
common target sites at promoters (E-Box), see figure 4. 
The outcome of this whole system is that; In the normal situation both 
homodimeric and heterodimeric populations of BR-HLH-Zip proteins exist at a 
level that is strictly regulated, and i f the level of one member of this system is 
altered as a result of a genetic change, regulation is lost with the consequence of 
neoplastic cell growth. 
1.5. Summary 
From what has been written so far, the following out-lines are drawn: 
• N-myc is a cellular oncogene, which seems to contribute to the growth 
control of cells. 
• The process of gene amplification usually involves co-amplification of 
extensive regions of DNA. 
• Co-amplification of the DDX1 gene is rare in neuroblastoma cells, and often 
limited to stage 4-4s. 
• N-/wyc co-amplifies with the ODC1 gene in one of six primary 
neuroblastomas. 
• The protein produced by N-myc oncogene is N-Myc, which is thought to be a 
putative transcription regulator (may be responsible for either "turning on" 
or "turning o f f other genes). 
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» N-zwyc normal activity may require a fine tuned interplay with at least two or 
more proteins, and might be regulated at least in part, through interaction 
with these proteins. 
• Enhanced levels of N-Myc could result in disturbance of the balanced 
interaction (with the other proteins). 
• N-Myc and Max work together in binding DNA, and probably enhanced 
levels of N-Myc lead's to a greater number of transcription activating 
complexes. 
1.6. Aim of research 
The aim of this project is to identify potential targets for N-myc regulation using 
the cell line SK-N-SH. 
SK-N-SH are human neuroblastoma cells; a metastasis from a bone marrow sample 
and comprise of two distinct populations of cells: 
N - type cells show neuroblastic morphology. 
S - type cells are large and epitheliod. 
Karyotype shows chromosomal translocation between chromosome 7 and chromosome 22, 
and finally this cell line has no amplification of the oncogene N-myc (low levels of N-Myc 
protein). 
N-myc target genes were isolated using a modification of the protocol developed to 
identify p53 binding sites [28], and as follows (see figure 5): 
• Generating NTG library, by isolating genomic DNA from SK-N-SH cells digested to 
completion with Sau3A and mixed with nuclear extract from SK-N-SH cells, and 
finally immunoprecipitated with N-myc antibodies. 
• DNA recovered from these precipitates was cloned into pBluescript SK+, and repeated 
immunoprecipitation on the primary N-myc selected library either: 
• In the presence of poly dldC -> +NTG clones. 
• Without competition -» -NTG clones. 
• 400 clones have been isolated, their size of insert calculated, and pure plasmid 
prepared for inserts larger than 300bp. 
• Inserts were then sequenced using reverse and universal primers. 
• DNA sequence homology searches have been carried out using the Daresbury data 
base. 
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2. Materials and Methods 
2.1. Materials: 
2.1.1- NTG library 
=> Solution I (Cell resuspension solution) 
• Glucose 50 mM 
• Tris.Cl (pH 8.0) 25 mM 
• EDTA(pH8.0) 10 mM 
• Autoclave at 15 lb. in" for 20 min. 
=> Solution I I I (Potassium acetate) 
- Per 100 ml: 
• KOAc(5M) 60 ml. 
• Glacial acetic acid 11.5 ml. 
• Autoclave at 15 lb. in" for 20 min. 
=> Sodium Acetate (3M) 
- Per litre: 
• NaOAc.3H20 408.1 g. 
• Adjust to pH 5.2 with glacial acetic acid. 
• Autoclave at 15 lb. in"2 for 20 min. 
=> 1 M Tris.Cl pH 7.5 
- Per litre: 
• Tris 121.1 g 
• Adjust to pH 7.5 with HC1. 
• Autoclave at 15 lb. in' for 20 min. 
=> Trypsin 
1 ml of Trypsin (Gibco BRL) + 10ml PBS/EDTA. Make up immediately prior to 
use. 
=> 1 M TRIS. pH (8) 
- Per 100mlH 2O: 
• 12.11 g 
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=> Solution I I (Cell lysis solution') 
• SDS 1% 
• NaOH 0.2M 
• Prepare a 2% solution of SDS and a 0.4 M solution of NaOH, separately. 
Autoclave at 15 lb. in' for 20 min. Mix 1:1 prior to use to give a 1% and 0.2 M 
solution. 
=> 0.5 M EDTA D H 8.0 
- Per litre: 
• EDTA Na 2.2H 20 186.1 g 
• Adjust to pH 8.0 in order that the EDTA will dissolve. 
• Autoclave at 15 lb. in"2 for 20 min. 
TFBI. 
• K O A c ( l M ) 6 m l ( f c 3 0 m M ) 
• RbCl 2.418 g(fc 100 mM) 
• CaCl2 (1M) 2 ml (fc 10 mM) 
• M g C l 2 ( l M ) 10ml(fc50mM) 
• Glycerol 30 ml (fc 15%) 
• H 2 0 to 200 ml. Adjust to pH 5.8 with 0.2 acetic acid (few drops). Filter sterilize, 
store 4°C. 
TFBII. 
• MOPS 0.2093 g (fc 10 mM) 
• CaC12(lM) 7.5 ml (fc 75 mM) 
• RbCl 0.1209 g(fc 10 mM) 
• Glycerol 15 ml 
• H 2 0 to 100 ml. Adjust to pH 6.5 with KOH (drop or two). Filter sterilize, store 
4°C. 
=> Ammonium Acetate 10M 
• 1.92gm./25mlH 2 0. 
=> Leupeptin 0.5 mg/ml 
• Dissolve 1 mg in 2 ml of sterile H 2 0 , store at -20°C. 
=> Pepstatin A 5 mg/ml 
• Dissolve 5 mg in 5 ml of ethanol, store at -20°C. 
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=> NETN 
• NaCl 100 mM 
• EDTA 1 mM 
• Tris.Cl pH 8.0 20 mM 
• Nonidet P-40 0.5 % 
• PMSF 1 mM 
=> PMSF 100 mM 
• Dissolve 17.4 mg in 1 ml of isopropanol, store at -20°C. 
=> Leupeptin 0.5 mg/ml 
• 7.5 ng in 100 ul NETN. 
=> RNAase A 
- 10 mg / 1ml buffer: 
• Tris.Cl (pH 7.5) 
• NaCl 
=> Proteinase K 
• 2 0 m g / l m l 
=> Ampicillin 
• 0.25 gm / 10ml of sterile water. 
=> TBS 
• Tris. ClpH7.5 20 mM 
• NaCl 500 mM 
=> X Hind I I I DNA marker 
- Set up the following digestion in an eppendorf: 
• H 2 0 780 ul 
• Buffer 10 100 ul 
• A, DNA 100 ul 
• Hind I I I 20 ul 
• Leave in the 37°C heat block overnight. 
• Add 100 j i l of 6X loading buffer, store at -20°C 
=> X Gal TDMFX Galactosidel 




=> Agarose gel 
• 0.8 % gel 0.48g Agarose / 60 ml I X TAE buffer 
• 1.2 % gel 0.72g Agarose / 60 ml 1X TAE buffer 
• 1.5% gel 0.9g Agarose / 60 ml 1X TAE buffer 
• 2.0 % gel 1.2g Agarose / 60 ml 1X TAE buffer 
=> Nutrient Broth (LABM) 
• 2.5g of labM Nutrient / 100ml H 2 0 
• Autoclave at 15 lb. in' for 20 min. 
• Add 200 j i l of Ampicillin before use 
=> Nutrient Agar (LABM) 
• 2.8g/100ml H 2 0 
• Autoclave at 15 lb. in*2 for 20 min. 
• Add Ampicillin-Xgal before use. 
=> PBS / EDTA 
- 5 PBS tablets (Dulbeccos phosphate w/o calcium or magnesium) + O.lg EDTA 
in 500ml of H 2 0 . 
- Aliquot into 100ml bottles and autoclave. Store at 4°C. 
Buffers: 
T.E. Buffer (pH 8.0). 
- Per litre: 
• Ttis.Cl (pH 7.5) 10 mM 
• EDTA (pH 8.0) 1.0 mM 
• Autoclave at 15 lb. in ' 2 for 20 min. 
I X TAE buffer 
- Per 5 litres: 
• 50XTAE 100 ml. 
6X Loading buffer 
• Bromophenol blue 0.25% (w/v) 
• Xylene cyanol f f 0.25% (w/v) 
• Glycerol 30% (w/v) 
19 
5 OX Tris-acetate electrophoresis buffer (TAE) 
- Per litre: 
• Tris 242.0 g. 
• Glacial acetic acid 57.1ml. 
• EDTA (0.5 M pH 8.0) 100 ml. 
Wash buffer 
- NENT containing: 
• PMSF 0.5 mM 
• Leupeptin 1 ug / ml 
• Pepstatin l u g / m l 
Dissociation buffer 
• Tris.Cl pH 9.0 500 mM 
• EDTA 20 mM 
• NaCl 10 mM 
• SDS 0.2% 
Extraction buffer 
• Tris.HCl (pH 8.0) lOmM 
• EDTA (pH 8.0) O.lmM 
• Pencreatic RNAase 20 |ig/ml 




• 100 mM EDTA 
• lOmMEGTA 
• lOOmMDTT 
• Add to H 2 0 final volume 100ml 
• Add PMSF to 0.5mM before use. 
10 ml (fc lOmM) 
4 ml (fc lOmM) 
20ul (fc O.lmM) 
lml (fc O.lmM) 
lml (fc ImM) 
IPX CIP dephosphorvlation buffer 
• ZnCl 2 lOmM 
• MgCl 2 lOmM 
• Tris.Cl (pH 8.3) 100 mM 
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Binding buffer 
Tris.HCl pH 7.5 20mM 
• Glycerol 4% 
• DTT 1 mM 
NaCl 50mM 
• EDTA O.lmM 
• Spermidine 2.5mM 
MgCl 2 7.5mM 
Leupeptin 1 u.g / ml 
• Pepstatin 1 fig / ml 
• PMSF 0.5mM 
CA/Mn buffer (DH5.5) 
• CaCl 2.2H 20 100 mM 
• MnCl 2 .4H 20 70 mM 




Prepare fresh and filter sterilize. Start with a solution of the NaOAc at pH 7.0, add 
the Ca and Mn, this will bring the pH down to nearer 6.0. Finally adjust the pH 
down to 5.5 with acetic acid, never adjust thepHup with NaOH. 
Make up to 42.5 ml filter sterilize and then add 7.5 ml of sterile glycerol for the 
buffer with 15% glycerol. 
=> Buffer C 
• 100mMHepespH7.9 20ml (fc20mM) 
• 4MNaCl 10ml (fc 0.4M) 
• 100 mM EDTA 1 ml (fc ImM) 
• 10 mM EGTA 10ml (fc ImM) 
• 100 mM DTT 1ml (fc ImM) 
• Add to H 2 0 final volume 100ml 
• Add PMSF to ImM before use. 
2.1.2- Colony blots 
- Preparation of solutions: 
=> SDS 10% 
=> Denaturing solution 
• NaOH 0.5 N 
• NaCl 1.5 M 
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:=> Neutralizing solution 
• NaCl 
• Tris.Cl (pH 7.5) 
1.5 M 
0.5 M 
=> 20X SSC 
- Per litre: 
• NaCl 175.3 g 
• Sodium citrate 88.2 g 
Adjust to pH 7.0 with 10 N NaOH. 
2.1.3- Filter hybridization 
- Preparation of solutions: 
=> Pre- hybridization 
Solution Volume 
• 20 X SSPE 12.5 ml 
• lOOXDenhardt's 2.5 ml 
• 10% [w/v] SDS 2.5 ml 
Concentration 
5 X SSPE 
5 XDenhardt's 
0.5% [w/v] SDS 






20 X SSPE 12.5 ml 
lOOXDenhardt's 2.5 ml 
10% [w/v] SDS 2.5 ml 
+ 3.5 ml H 2Q + 100 ul 0.5 M EDTA. 
Concentration 
5 X SSPE 
5 X Denhardt's 
0.5% [w/v] SDS 
2.1.4- Protein Analysis 
- Preparation of solutions: 
Protein stain 
- Per litre: 
• H 2 0 
• Methanol 




• Coomassie brilliant blue R250 1 g 
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=> SDS page sample buffer 
• H 2 0 4ml 
• 0.5 M Tris.Cl (pH 6.8) 1.0ml 
$ Glycerol 0.8ml 
• 10% SDS 1.6ml 
• P Mercaptoethanol 0.4ml 
• 0.1% Bromophenol blue 0.2ml [of lmg in 1ml H 2 0 ] 
• Store in -20°C 
=> 45% Acrvlamide solution 
• 22.5g in 50 ml H 2 0 
=> 1.6% Bisacrylamide 
• 0.32 in 50 ml H 2 0 
=> 1.5M Tris.Cl fpH 8.8) 
=> 4% SDS 
• 0.1 SDS 
2gm SDS + 50ml H 2 0 
=> SDS page electrophoresis buffer 
- Per 3 litre: 
• Tris 9.1g 
• Glycine 43.2g 
• SDS 3.0g 
^> 12.5% Resolving gel 
• 45% Acrylamide 2.78ml 
• 1.6% Bisacrylamide 0.64ml 
• 1.5M Tris pH 8.8 2.5ml 
• 4% SDS 0.26ml 
• H 2 0 3.82ml 
• TEMED 13.2ul 
• 0.56% APS 0.5ml 
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Protein stain 
- Per litre: 
$ H 2 0 450ml 
0 Methanol 450ml 
Acetic acid 100ml 
0.65% APS (ammonium persulphate) 
- Prepare fresh when needed: 
* 11.2mg in 2ml H 2 0 
4% Stacking gel 
• 45% Acrylamide 0.7ml 
• 1.6% Bisacrylamide 0.55ml 
• 0.5M Tris pH 6.8 2.0ml 
• 4% SDS 0.4ml 
• H 2 0 4.6ml 
• TEMED 12ul 
• 0.56% APS 0.55ml 
2.2. Methods: 
2.2.1. Tissue culture 
2.2.1.1- Recovering SK-N-SH cells from liquid Nitrogen 
Cells were removed from the freezer, thawed by gently swirling the tube in a 
beaker of water at 37°C and then transferring the contents to a sterile 25ml 
universal. 5ml of media (RPMI 1640 Medium with Glutamax-1, from GIBCO 
BRL) was then added slowly over a period of 2 minutes. 
Cells were then pelleted at 1500rpm for 2 minutes at room temperature, and re-
suspended in 1ml of medium containing 10% FCS. The contents were then 
transferred to a 25cm flask, a further 2ml of medium was added and incubated at 
37°C in a 5% C 0 2 incubator overnight (until cells attach). 
[Media was changed every 3-4 days] 
2.2.1.2- Trypsinisation of cells for passaging 
Medium was decanted from the cells, which were then washed twice with 
PBS/EDTA, ensuring all surfaces of the flask as well as the monolayer were 
covered. 
2.5ml of Trypsin was added to rinse the cells and then poured o f f leaving a thin 
f i l m of trypsin covering the cell surface. 
The sealed flask was then placed in 5% C 0 2 incubator for one minute or until cells 
were rounded up and detached. 
3 ml of medium + 10% FCS was added to the cell suspension to inhibit trypsin and 
then decanted into a sterile 25ml universal. 
The flask was then rinsed with a further 5ml of medium and decanted into the 25ml 
universal. The cells were centrifuged at 1500rpm at room temperature for 2 
minutes, then, after pouring o f f the medium 1ml of fresh media was added and 
aspirated to a single cell suspension. The contents were then transferred to a 25cm 
flask and an appropriate volume of medium containing 10% FCS (2ml) was added. 
The flask was then kept in a 5% C 0 2 incubator at 37°C overnight (changing 
medium every 3-4 day). 
2.2.1.3- Preservation of cells in liquid Nitrogen 
Cells had to be trypsinized first (previous method) but re-suspended in 1ml of 90% 
FCS / 10% DMSO. 0.5ml of cell suspension was added to NUNC Cryovials (screw 
tops finger tight), and placed at -20°C for 30 minutes and then transferred to an 
insulated box at -70°C overnight, then to a liquid Nitrogen storage container. 
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2.2.2. DNA Manipulation 
To begin the research, a number of NTG clones are required (which may have N -
Myc target genes). These clones are generated from what is called the N-Myc 
binding library. In order to begin the library, a number of preparations are 
required, for example: Competent sure cells, Genomic DNA, Nuclear extraction, 
Competent DH5 oc cells, pBluescript SK+. 
2.2.2.1- Complete sure cells 
5ml of culture was grown overnight (E.Coli) and then using l m l (5ml) to inoculate 
100ml of pre-warmed LB, left to grow at 37°C until OD 6 0 0 =0.5, the cells were then 
centrifuged in 50ml aliquots in falcon tubes. 
The pellets were re-suspended in lA the volume of ice-cold Ca/Mn buffer and after 
1 hour incubation on ice, centrifuged at 200rpm for 5 minutes and re-suspended 
very gently in 1/20 the volume of ice-cold Ca/Mn buffer + 15% glycerol and 
finally dispensed in 200 \i\ aliquots into cold eppendorfs, frozen in liquid Nitrogen 
and transferred to ice (stored at -80°C). 
2.2.2.2- Competent DH5 oc cells 
5ml of culture was grown overnight, and l m l was used to inoculate 100ml of pre-
warmed LB, it was then left to grow at 37°C until O D 6 0 0 reached 0.3-0.35. The 
cells were then chilled on ice for 5 minutes and pelleted using the MSE mistral for 
7 minutes at 3600rpm, 4°C and re-suspended in 2/5 the volume using TFBI, left 
again on ice for 5 minutes, pelleted down, re-suspended in 1/25 the volume using 
TFBII and finally dispensed in 200|il aliquots into pre-chilled eppendorfs and 
frozen in liquid Nitrogen (stored at -80°C). 
2.2.2.3- Isolation of Genomic DNA 
I - Preparation of cells 
SK-N-SH cells growing in monolayer: 
a- Cells were detached from the dishes by trypsinisation and recovered by 
centrifugation at 1500 rpm at 4°C for 10 minutes, 
b- Cells were re-suspended in 5-10 volumes of ice-cold TBS and recovered again 
at 1500rpm at 4°C for 10 minutes, 
c- Re-suspended in l m l TE, 10ml of extraction buffer was added and incubated for 
1 hour at 37 °C. 
I I - DNA Extraction 
a. After 1 hour of incubation proteinase K was added to a final concentration of 
100 u.g/ml (50 ul of 20 ml/ml stock) and incubated at 50 °C for 3 hours with 
periodic mixing. 
26 
b. Af te r 3 hours of incubation the solution was left to cool down at room 
temperature and extracted wi th an equal volume o f Phenol equilibrated wi th 0.5 
M Tris-HCl pH 8.0 and was left to mix gently for 2 minutes on a rocking 
platform. 
c. The solution was then centrifuged at 5000g for 50 minutes at room temperature, 
then the aqueous layer was carefully transferred to a fresh tube. 
d. Step b & c was repeated twice more. 
e. For isolating D N A in the size range 100-150Kb a 0.2 volume o f 10M 
ammonium acetate and 2 volumes o f ethanol was added at room temperature 
(swirled until thoroughly mixed), and the D N A precipitate was removed wi th a 
sterile needle or by centrifugation i f ( D N A fragments). 
f. D N A pellet was washed twice wi th 70% o f ethanol and re-dissolved in 1ml o f 
TE for each 5X10 6 cells by gently rocking the solution for 12-24 hours. 
g. 5(0.1 o f D N A Extraction was run on a 0.8% gel to check D N A presence and 





Kb . . . 
: 
mm m 3.03 Kb 
Figure 2 . 1 , 5u l o f D N A extraction on 0.8% Agarose gel. 
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I l l - Sau3A Genomic D N A 
The fo l lowing were mixed: 
a. lOOul of Genomic D N A . 
b. 20ul o f buffer 2. 
c. lOul of Sau3A. 
d. 70ul of H 2 0 . 
and incubated for 5 hours at 37°C, then precipitated with 20ul of Sodium 
Acetate and (Ethanol, 70% Ethanol at -20°C) . The pellet was then re-suspended in 
20ul o f H 2 0 . (see figure 2.2) 
2 m 
Marker 
23-13 Kb M 
9*Z fcb 




Figure 2.2, 2\i\ o f Sau3A cut genomic D N A on 0.8% Agarose gel. 
2.2.2.4- Nuclear Protein Extraction 
a. Cells (SK-N-SH) were scraped from tissue culture flasks into TBS (5ml), and 
the flasks were washed wi th a further 2ml of TBS. 
b. Cells were then pelleted at 6500rpm in a refrigerated centrifuge for 2 minutes 
and re-suspended in 2ml o f TBS. then transferred to an eppendorf tube, 
pelleted in MSE mistral at 6500rpm for I 5 seconds. 
c. TBS was then removed and the pellet re-suspended in 400ul of cold buffer A, 
swelled on ice for 15 minutes then 25ml of 10% Nonidet NP-40 was added. 
d. After 10 seconds of vortexing the nuclei were pelleted at 6500rpm in MSE 
microcentrifuge for 30 seconds and re-suspended in 50ul of ice cold buffer C, 
the nuclei were then left on ice for 15 minutes with occasional shaking. 
e. Lysed nuclei and other debris were removed by centrifugation at 13000rpm, 
40°C for 50 minutes (store at -70 °C). 
2.2.2.5- pBluescript SK+ 
I - Preparation of pBluescript 
a. 3ml of culture was grown overnight (pBluescript SK+ cells) centrifuged for 3 
minutes and re-suspended in 200ul of ice cold solution. 
b. 200|il of solution I I was added and mixed by gentle inversion, then mixed with 
200fil of ice cold solution I I I . The solution was then centrifuged at fu l l speed in 
a microfuge for 5 minutes to pellet the precipitate. The supernatant was then 
transferred to a clean eppendorf (avoiding pipetting up any of the precipitate) 
and centrifuged once more for 1 minute. 
c. The supernatant was transferred to a clean eppendorf tube and 2 volumes of 
absolute ethanol (at -20 °C) was added then left on ice at least 15 minutes. 
d. The solution was centrifuged at fu l l speed for 15 minutes. The ethanol poured 
o f f and 1 ml of 70% ethanol (at -20 °C) was added, centrifuged for 3 minutes 
and ethanol poured off. 
e. The pellet was then re-suspended in 30fil of H 2 0 . 
f. 2ul was run on a 0.8% gel to check the presence of pBluescript. 
I I - BamHl pBluescript 
The following were mixed: 
a. 50|iil pBluescript. 
b. 10ul Buffer 4. 
c. lOul BamHl. 
d. 30uIH 2 O. 
Left for 3 hours at 37°C, then precipitated with 2 volumes of Ethanol, centrifuged 
and the pellet washed with 70% Ethanol at -20°C. The pellet was then re-
suspended with 40(il of H 2 0 . 
10|il is kept as a non CIP (Calf Intestinal Alkaline Phosphates) BamHl pBluescript 
(2ul was run on a 0.8% gel), (see figure 2.3) 
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Figure 2.3, 2|il of BamHl pBluescript on 0.8% agarose gel. 
The remaining 3ul was dephosphorylated wi th CIP. This was done by the 
fo l lowing method. The fo l lowing were mixed: 
a. 30(j.l o f BamHl pBluescript. 
b. 10|il o f (10 X CIP dephosphorylation buffer) . 
c. 6 0 u l o f H 2 O . 
d. l u l o f C I P . 
Af te r 30 minutes incubation at 37°C the fo l lowing was added: 
a. 50ul o f 2% SDS b. 10uJ o f lOOmM E D T A 
c. 2ul o f lOmg/ml Proteinase K . d. 38ul o f H 2 0 
Incubate again at -56°C for 30 minutes. The solution was then extracted wi th 200ul 
o f Phenol : Chloroform, centrifuged for 3 minutes, transferring aqueous layer to a 
fresh tube, and a further 200ul o f Phenol was added. 
The solution was then precipitated wi th 20|j.l o f Sodium acetate and 2 volume o f 
Ethanol, 70% Ethanol, and f ina l ly the pellet was re-dissolved in 15ul o f H 2 0 . 
(2(j.l o f CIP BamHl pBluescript was run on a 0.8% gel), (see figure 2.4) 
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Figure 2.4, 2ul of CIP BamHl pBluescript on 0.8% Agarose gel. 
2.2.2.6- Preparation o f N-mvc Binding library 
Genomic 
Isolation 
Digest with Sau3A\^ 
SK-N-SH 
Protein isolation 
i (nuclear extract) 
into fragments 
Add N-myc antibody 
Immunopr e cipitate 
to isolate ^ S 5 
DNAwith ^ 
N-myc bound \ / J ^ f c / - . 
/ ^ O -
Clone ^ — 
recovered DNA into 
BamHl pBluescript 
NTG clones 
N-Myc will bind to DNA 
with an E-Box 
Repeat immunoprecipitation either: 
with poly did C —• NTG + Clones 
without poly did C —• NTG - Clones 
400 clones have been isolated 
Figure 2.5, Stage explanation of preparation of N-myc binding library. 
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I - First round o f screening 
a. The library was started by mixing the f o l l o w i n g : 
1. lOugof Sau3A D N A 
2. 50uf o f Nuclear extract 
3. In a total volume o f 100u.l o f binding buffer and incubating at room 
temperature for 1 hour. Then.2 ( igof N-myc antibody was added. 
b. Af te r 1 hour o f incubation at room temperature, protein A - sepharose (7.5mg in 
1 OOfj.1 N E T N buffer ) was added, then mixed and incubated for a further 30 
minutes. The solution was then washed twice in washing buffer (30ul) and the 
D N A dissociated in 200ul o f dissociation buffer at 55°C for 30 minutes. 
c. 200u.l o f Phenol-Chloroform was used to extract the D N A (aqueous layer) 
which was then precipitated w i t h ' / 3 Volume o f ethanol for 16 hour at -80°C. 
d. The D N A was recovered by 15 minutes centrifugation and re-dissolved in 10u.l 
H 2 0 , then cloned into BamHl pBluescript (ha l f treated w i t h CIP), and then sure 
cells transformed wi th vector. 
I I - Ligat ion 
a. CIP B a m H l pBluescript 
The f o l l o w i n g were mixed: 
1. 5 u g o f D N A . 
2. lOul o f CIP pBluescript. 
3. 4u l o f ligase buffer (5X) . 
4. 1 u,l o f ligase. 
b. Non CIP BamHl pBluescript 
The f o l l o w i n g were mixed: 
1. 5 ug, o f D N A . 
2. 8 fj.1 pBluescript. 
3. 4 \il o f ligase buffer. 
4. 1 [i\ o f ligase 
5. 2ul o f H 2 0 . 
Both were stored in 4°C overnight to ligate. 
I I I - Sure cell transformation 
a. The 20ul o f CIP ligation was split into 2 eppendorts, each o f them had the 
f o l l o w i n g : 
1. lOul o f l igation. 
2. 4 0 u l o f T E . 
3. lOOul o f Sure cells. 
They were lef t on ice for 30 minutes, then heat shocked at 37°C for 5 minutes, 
diluted in to 1ml o f pre-warmed L B (each eppendorf), and f ina l ly lef t shaking for 
1-2 hours (100 minutes optimum) at 37°C, then both tubes were centrifuged, the 
media decanted and re-suspended in 50ul o f L B . 
Both 150ul were plated out on the same plate and incubated at 37°C overnight. 
(Plates had A m p i c i l l i n + X Gal) 
[The same method was used for the non CIP BamHl pBluescript l igat ion] 
b. Transformants were scraped o f f into 1.5ml L B and prepared plasmid D N A f r o m 
750ul, for each CIP treated and non CIP, the other 750 | i l was stored as glycerol 
at -80°C. 
IV- Preparation o f plasmid D N A 
a. The transformants were pelleted at f u l l speed in a microfuge for 3 minutes and 
discarding the supernatant, 200ul o f solution 1 was added to resuspend the cells 
plus 4u l o f RNAseA o f ( lOmg R N A / l m l Tr ic .Cl+NaCl buf fe r ) . 
A further 200ul o f solution was added and mixed by gentle inversion, and f ina l ly 
200|LI1 o f solution I I I was added and mixed by shaking. 
b. The precipitate was pelleted at f u l l speed in a microfuge for 5 minutes, and 
extracted w i t h an equal volume o f Phenol: Chloroform. 
The aqueous layer was transferred to a clean eppendorf tube and Ethanol 
precipitated, f ina l ly , re-suspending the D N A pellet in 22 | i l H 2 0 . This method was 
used for both CIP transformants and non CIP transformants. 




Figure 2.6, 2|il of plasmid DNA for CIP transformants on 0.8% Agarose gel. 
V- Second round o f screening 
The fo l lowing were mixed: 
1. 15ul o f CIP (whole plasmid). 
2. 50ul o f Nuclear Extract. 
3. 0.5ul o f l ( i g / u l poly (dIdC)-[to generate NTG + colonies or without 
competitor to generate NTG-colonies] 
4. In total volume o f 100(il o f binding buffer. 
Then the procedure f rom 6-1- to 6-3-a o f the first round was repeated (large 
ampici l l in - X Gal plates were used, 500ml agar on each plate). 
The plates had a large number o f N T G clones (whites). A total o f 400 clones were 
picked, restreaked on to new ampici l l in plates and given a number (Exp NTG + 1). 
For each N T G clone a 3 ml . overnight culture was grown in order to isolate the 
plasmid D N A . A 2ul aliquot o f each plasmid was run on a 0.8% gel and then after 
digesting the insert D N A wi th SacI/EcoRI, run on a 1.2% gel and calculating the 
size o f insert using a standard graph. 
Different sizes of insert were chosen (larger than 300 bp), and pure plasmid D N A 
was prepared using a QIA prep plasmid kit (By QIAGEN) . 
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The inserts were then sequenced by Julea Bartley using an A B 1 373A automatic 
D N A sequencer using the reverse (RV) and universal (UP) primers, then the 
sequence was transmitted to SEQNET Daresbury and compared to D N A and 
protein databases using the FASTA and GAP algorithms. Candidate homology 
were selected based on high similari ty over an extended length compared w i t h the 
actual length o f the inserts and an assessment o f their potential significance to 
neuroblastoma. 
2.2.2.7- Isolation o f plasmid D N A 
This method was used for each o f the 400 clones, stored at -20°C unt i l needed. 
Cells were pelleted f r o m a 3ml overnight culture at f u l l speed in a microfuge 
for 3minutes, and then re-suspended in 200u,l o f solution 1 pipetting. 
A further 200ul o f solution I I was added and mixed by gentle inversion, and 
f ina l ly 200f i l o f solution I I I is added and mixed by shaking. The solution was then 
centrifuged at f u l l speed in a microfuge for 5 minutes to pellet the precipitate. 
The supernatant was transferred to a clean Eppendorf tube, and Ethanol 
precipitated w i t h (Ethanol/ 70% Ethanol). The D N A pellet then re-suspended in 30 
ul o f T.E. containing RNAase (900ul o f T.E. + lOOul o f RNAase). 
A small sample was then run on a 0.8% agarose gel (2u l D N A , 8(il o f sterile water, 
2 f i l o f loading buf fe r ) . 
2.2.2.8- SacI / EcoRI double digest 
The f o l l o w i n g were mixed: 
a. 1 4 u l o f H 2 0 . 
b. 2ul o f D N A (NTG) . 
c. 2ul o f buffer 2. 
d. l u l o f SacI. 
e. 1 JLLI o f EcoRI. 
Incubated at 37°C for 1-2 hours, then 4 [ i l o f loading buffer were added and run on 
a 1.2% agarose gel using the X Hind III D N A marker. 
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2.2.2.9- Insert size calculation 
A f t e r digesting out the insert D N A w i t h SacI/EcoRI, a standard curve was drawn 
using the standard sizes o f the X Hind III D N A marker and the distance in 
mill imetres for each size. 
114 N T G clones have been plasmid prepped, digested w i t h SacI/EcoRI, and the 
size o f insert calculated for each one. Out o f the 114, 5 NTG ' s were chosen (wi th 
different size o f insert) partially or f u l l y sequenced, each had been sequenced 
using RV-UP and sent for Homology search. 
The procedure for each N T G clone is explained i n details in later sections. 
2.2.2.10- Colony Blots 
Colony Blots were done in order to do check i f any clones had been previously 
isolated 
N T G clones were plated onto new ampic i l l in plates (100 on each plate) and 
incubated at 37°C overnight. 
A nylon membrane was cut into pieces sl ightly smaller than the agar plates, and 
each membrane was labelled for identif icat ion purposes, then placed label side 
down on to the re-streaked plate, making sure no air bubbles were trapped. 3 
asymmetrical marks were made by stabbing through the membrane and the agar 
(wi th a sterile needle) for later realignment, f r o m this point the membrane was 
handled w i t h blunt forceps. 
The membranes were then transferred (bacteria side up) to a piece o f whatman 
3 M M paper soaked in 10% SDS and lef t for 3 minutes (This w i l l break the cell 
wa l l and release the D N A ) . A f t e r 3 minutes the excess SDS was wiped o f f and the 
membrane transferred to 3 M M paper soaked in Denaturing solution, and lef t for 5 
minutes. Denaturing solution converts the double strand D N A to single strands so 
it sticks to the membrane. 
A f t e r the excess denaturing solution was wiped o f f and the membrane transferred 
to a piece o f 3 M M paper soaked in neutralizing solution for 5 minutes and f ina l ly 
to a 3 M M paper soaked in 2XSSC for 5 minutes. 
The membranes were then transferred to a piece o f dry 3 M M paper and a l lowing to 
air dry for 30 minutes, wrapped in c l ing f i l m , and placed bacteria side down on the 
U V transilluminator for 5 minutes. To store at room temperature they were 
wrapped in t in f o i l . 
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2.2.2.11- Colony Hybridizat ion 
Colony Hybridizat ion was done to check i f any o f the 400 N T G clones have picked 
the same insert as the one in clone N T G - 2 1 . 
NTG-21 is thought to be a target gene for N-myc, and has been isolated f r o m a 
N T G library using the cell line SK-N-Be2c (This cell line has 150-fold N-myc 
oncogene amplif icat ion) . NTG-21 contains an 803bp insert and shows 65% identity 
over 415bp to the 3' end o f intron 1 o f the human aromatic L-amino acid 
decarboxylase gene (DOPA decarboxylase) gene, and as mentioned before, one o f 
Neuroblastoma's distinguished molecular characteristics is the increased 
catecholamine metabolism and high expression o f DOPA decarboxylase. This 
appears to be a l ink between N - M y c expression and catecholamine metabolism. 
I -
Sau3A Sau3A 
SacI 803 bp Insert EcoRI 
Figure 2.7, NTG-21 
NTG-21 was digested f i rs t w i t h SacI/EcoRI as fo l lows: 
a. 17ul D N A . 
b. 4[i\ SacI. 
c. 4u l EcoRI. 
d. 8ul buffer (2). 
e. 4 7 H 2 0 . 
A f t e r 3 to 4 hours in 37°C, 16ul o f loading buffer was added, and run on a 
0.8% agarose gel. The fragment was then isolated f r o m the gel as fo l lows. 
I I - Isolation o f D N A f r o m Agarose gels 
Af t e r electrophoresis, the band o f interest was cut using a clean razor blade, 
t r imming o f f all excess gel. The slice o f gel was then put into a labelled eppendorf 
and 800| i l o f sodium iodide added, then placed in a water bath at 70°C for 5 
minutes, or unt i l the agarose had completely melted. 
A f t e r leaving i t for 5 minutes at room temperature 5u,l o f silica fines was added (to 
re-suspend) and vortexed for 1 second, the tube was then inverted continuously for 
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After the SacI/EcoRI digest isolation it was then digested wi th SauSA as fol lows: 
a. 48|ul D N A . 
b. A\x\Sau3A. 
c. 8|il buffer. 
d. 40ul H 2 0 . 
e. 3 to 4 hours in 37°C heat block, run on 0.8% agarose gel and then 
isolating the 800pb band using the previous method (isolation o f D N A 
f rom agarose gels). 
f. 5\x\ o f the 800 NTG-21 was run on a 0.8% agarose gel. (see figure 2.9) 
iiliilli 1 1 
• ;0-j'-':; 7' 111 
Fft*l*::::::M 
a s — 
Figure 2.9, 5|al of Sau3A cut NTG-21 on 0.8% Agarose gel. 
Colony hybridization was then carried out using the multiprime D N A 
labelling reaction kit . 
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2.2.2.12- Glycerolstocks 
Glycerol stocks were prepared in order to store all the 400 N T G clones unt i l 
needed. 
Method: 
5ml o f broth was incubated in a 15ml falcon tube, w i t h bacteria ( N T G clone) 
and grown overnight w i t h shaking. 
The cells were pelleted by centrifugation for 2min, pouring o f f the medium and 
resuspending the pellet in 0.5ml o f fresh medium, and then transferred to sterile 
eppendorf tube and adding 0.5ml o f slightly warmed sterile glycerol, shaking we l l 
to mix thoroughly, and stored at -70°C (Aseptic technique was used throughout and 
close to the bunsen flame as possible). 
2.2.2.13- Protein analysis 
This was done using protein extract f r o m SK-N-SH cells and SK-N-Be2c to 
compare the protein levels in both cells. 
I . Bradford protein assay 
a- Prepared 100ml o f a 1:5 di lu t ion o f Bio-Rad protein assay Dye reagent 
concentrate (20ml dye + 80ml H 2 0 ) . 
b- Dissolved l l m g o f Bovine serum albumin fraction V in 10 m l o f H 2 0 . 
c- Prepared the fo l l owing dilutions in eppendorf tubes: 
Tube Volume of BSA (1.1 mg/ml) Volume of Assay buffer Protein 
No. (^1) (ug) 
1 0 500 0 
2 45.5 454.5 5 
3 90.9 409.1 10 
4 159.1 340.9 17.5 
5 227.3 272.7 25 
6 318.2 181.8 35 
7 409.1 90.9 45 
8 500 0 55 
Table 2.1. 
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d- Prepared 50ul o f each standard (above) in to duplicate test tubes, 2.5ml 
o f diluted dye was added and incubated for 10-15 minutes at room 
temperature, read O D 5 9 5 n n i ) g r a p h was produced-
For sample between 5 and 50 | i l o f protein extract was added to a 2.5ml o f 
diluted dye, incubated for 10-15 minutes at room temperature, and then read 
O D 5 9 5 . 
The value for protein ug was read f r o m the standard curve and calculated the 
value for | ig protein/ul (explained in chapter three). 
I I . Protein analysis 
Method: 
The SDS-Polyacrylamide gel was performed using a resolving gel, on top 
the stacking gel overlaid w i t h 0 . 1 % SDS which is the poured o f f once gel sets. 
The samples were prepared as fo l lows : 
SK-N-SH SK-N-Be2c 
l O u l N / E 6 .25u lN /E 
+ + 
lOul Dye (SDS buffer ) lOul Dye (SDS buffer ) 
Both samples were boiled for 5 minutes to al low the SDS to denature the N / E 
(Neuroblastoma protein extract). 
A 16|il o f each was loaded in to the SDS gel wells w i th 16ul o f the standards 
(molecular size marker f r o m Sigma). A f t e r 1-2 hours, the gel was stained by 
immersing the gel in a min imum o f 5 volumes o f staining solution, and placed on a 
slow rotating p la t form for at least 4 hours at room temperature, and then de-stained 
by soaking it in the destaining solution for 4-8 hours on a rocking p la t form, 
changing the destaining solution three or four times. The result is in chapter I I I . 
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3. Resul t s 
3.1- N T G clones and homology search 
The aim o f the research was to identify potential N-Myc target genes (NTGs) 
using the cell line SK-N-SH which has no N-myc amplification. This was done by 
generating an N T G library /(see Materials and Methods) 
The N T G library was prepared by isolating genomic D N A from SK-N-SH cells, 
digesting to completion wi th Sau3A, and then mixing wi th nuclear extract f rom 
SK-N-SH cells, to allow N-Myc to bind to D N A with an E-box (either high, or low 
a f f i n i t y ) . 
N-myc antibody was added and DNA-prote in complexes immunoprecipitated to 
isolate D N A wi th N - M y c bound. D N A fragments were then inserted into cloning 
vectors [BamHl cut pBluescript], then sure cells transformed wi th vector, see 
figure 2.5 . 
This procedure was repeated four times using different amounts of material each 
time to generate the genomic library w i t h 400 white clones. Plasmid D N A was 
then isolated f rom 114 white transformants, digested w i t h EcoRI/SacI, and run on 
agarose gels to estimate the insert sizes, (figures 3.1.a & b shows examples of 
these gels) using XHindlll D N A marker. 
m mm 
m HI +J3 
Figure 3.1a, Figure 3.1b, 
2 u l o f a number o f plasmid D N A digested w i t h EcoRI/SacI on 0.8% Agarose gel . 
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The size o f insert in 114 clones were calculated for the second time using the 
lOObp ladder as a marker to give accurate reading (photos not included). 
N T G clone Approx. size NTG clone Approx. size 
1 1700 bp 26 1220 bp 
2 680 bp 27 735+660+195+185 
3 1400+720+320+180 33 1350+140 bp 
5 1450 bp +390 bp 36 1550 bp 
7 2250 bp 40 1550 bp 
8 1300+760+240 bp 45 1450 bp +370 bp 
9 1490 bp 48 1600 bp 
12 1450 bp 52 1500 bp 
13 740+660+200+190 54 1600 bp 
17 1150 bp +420 bp 56 1400 bp 
19 1450 bp 
Table 3 .1 . 
Out of the 114 NTG's, the fo l lowing were chosen randomly: NTG+13, NTG+5, 
NTG+8, NTG+33. From each, pure plasmid was prepared and partially or f u l l y 
sequenced. 




Figure 3.2a, Figure 3.2b, Figure 3.2c, 
1 ul o f pure plasmid (+13, +5. +8, +33) on 1 .2% Agarose gel. 
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Each insert was partially or f u l l y sequenced using the reverse ( R V ) and universal 








Sequence E.Box Homology 
search 
5 1137 bp Partial 
8 956 bp Partial * 
13 1014 bp Partial * 
33 1210 bp R V . * * 
Table 3.2. 
NTG+5 
• Insert size approximately 1137bp. 
• Sequenced in i t i a l ly using R V and UP shown in f igure 3.5, ( D N A sequence and 
predicted restriction map as in f igure 3.4.1 & I I ) . 
• Homology search using the Daresbury databases shows the f o l l o w i n g : 
5u 
1 " 
gb_pr:hummh a3c7b 1 
LOCUS HUMHHA3C7B 8892 bp UNA P R I 31-MAR - 1 9 9 5 
J E F I N I T I O N Homo s a p i ens MriC c l a s s . - I a l p h a cha i n g e n e / l e a d e r e x o n / a l p h a 1 ana 
2 exons IHLA A3/ C 7 , Bry- B f S , C A 3 , C4Bl/> OR2/ D36 ) . 
A C C E S S I O N LP9411 
N E Y W I H U S c e l l s u r f a c e ant i gen ; e e l I s o r f a c e g l y c o p r o t e i n ; c l a s s I gene I 
i n t e g r a l membrane p r o t e i n J m a j o r h i s tocoiiipat i b i I i t y coniP l e x . . . . 
SCORES I n i 1 1 : 481 I n i t n: 7 38 Opt : 592 
70 .0! ; i d e n t i ty i n 316 bp o v e r l a p 
Figure 3.3.1, 
S u / r e v 
9 b _ o r : h u m t n f i 
LOCUS HUMTNFZ 10950 bp DM/V PR I 
D E F INI 11Otf HUman (rUrtor h e c r o s i s f a c t o r r e c e p t o r / 3 ' f U n k 
fcCCESSION M 3 i t « 
KEYWORDS tumor n e c r o s i s f a c t o r r e c e p t o r . 
SOURCE Homo s a p i e n s ( l i o r a r y : ESOpcD) ON*. 
ORGANISM Homo s a p i e n s . . . 
2 5 - M A - : - l / 9 2 
S C u R E S I n i t l : 250 I n i t n : 733 Opt 




5 u / r e v 
<j b _p r : hu mb'T y n 7 
LOCUS H I I M 8 H V H 7 23438 bp OtJ/\ PR I 
D E F I N I T I O N Homo s a p i e n s ( c l o n e s la.nbda j ^ H C 1 , ?., 3 arid M 
c t i a i n (WYH7) ' lene/ c o n p l e t e c d s . 
A C C E S S I O N M57<J5S ^30663 M5O604 M30o03 ^5 77<.7 fi D 7 / A 8 M577<,-J 
fCEYUOHOS be t a-aiyos i fi ri e a v y c h a i n ; c a r d i a c myos in heavy c h a i n . 
S O U R C E Human L s U K o c y t e UNA. . . . 
3 1 - 0 C T - 1 9 9 4 
e t a - m y o s i n neavy 
S C O R E S I n i t l : 296 l n i t n : 326 O p t : 660 
75-9% i d e n t i t y i n 29 4 bp O v e r l a p 
Figure 3.3.Ill, 
q b _ n r : n u m a t p s y o 
LOCUS HUMMPSY8 \0l86 DO P N A P R I 3 1 - 0 C T - W 9 4 
O E F I N I I I O M Humeri ^ Tp s y n t h a s e b e t a s u o u n i t ( A T P S S ) g e n e , c o « i p l » t » c J s 
A C C E S S I O N M 2 7 1 3 2 ' ' 
KEYWORDS ATP s y n t n a s e b e t a s u u u n i t . 
SOURCE human f e t a l l i v e r DNA, c l o n e q - b e t a - I ambaa 1 . 
UKCANISM Ho.no s a p i e n s . . . 
S C u R E S I n i t l : 306 I n i t n : 724 Opt : 512 
6 9 . 1 : . i d e n t i t y i n 330 bp o v e r l a p 
Figure 3.3.IV, 
5 u / r e v 
g b_p r : h s h w2 
LOCUS HSHW 2 22677 bp DNA PR I 12-MAY-1995 
D E F I N I T I O N Human DNA s e q u e n c e f rom cosmid HW2, H u n t i n g t o n ' s D i s e a s e R e g i o n 
chromosome 4 p l 6 » 3 . 
A C C E S S I O N £ 4 9 2 5 0 
KEYWORDS 4 p l 6 „ 3 ; CpG i s l a n d , " ne I i x~ I oop-h e I i x ; t r a n s c r i p t i o n r e p r e s s o r . 
SOuRCE human. . . . 
SCORES I n i t l : 346 I n i t n : 777 Opt: 645 




_p r : n u m t c r o 
LOCUS HUMTCRB 684V73 bp ONA P R I 1 4 - J A N - I V V 5 
D E M O T I O N Homo s a p i e n s ( c l o n e s : £1*1*, K 3 5 , K2l, K 5 6 , X 2 1 8 , G 5 4 , H 1 3 7 , H 1 8 , 
r U B / G 1 5 g 3 p , 6 1 5 , X 1 4 , A ? 7 , M i l , A H , H 7 . I , H 1 2 . 1 8 , H130 , A l o , 
C 2 1 5 , 6 1 , C68, C 2 I , A l l , X 6 A , CBG1, C B G l / C 2 v c j a p , and C29) g e r m l i n e 
T - c e t L r e c e p t o r b e t n c n ^ i n , cornel-? t? gene . 
A C C E S S I O N L360 9 2 . . . 
SCORES I n i t l : 1 U I n i t n : 2 54 Op t : 106 
Y0.6% i d e n t i t / i n 13 7 bp o v e r l a p 
Figure 3.3.VI, 
5 u / r e v 
g b _ p r : h u m l d l r a c 
L O C U S H U H L D L R A C 2S$d bp L ^ A PR I 0 7 - J A N - 1 9 9 5 
D E F I N I T I O N human a c e t y U t e d low d e n s i t y I i 0 0 2 r o i e i n C A C L D L I r e c e p t o r ( L U L H ) 
9 e n e , promoter and exon 1 . 
A C C E S S I O N M ? 3 1 8 V 
K E Y V / . J K D S L D L r e c e p t o r ; a c e t y l a t e d L U L r e c e o t o r ; 
loU d e n s i t y l i p o p r o t e i n r e c e p t o r . . . . 
S C O R E S I n i t l : 2 3 1 I n i t n : 7 2 9 Opt : 7 3 6 
£ 9 - 5 ' ; i d e n t i t y i n 4 6 9 bp o v e r l a p 
Figure 3.3.VII, 
5u 
q b_p r : rtu mi n s r d 
LOCllo HUMlNSKD 7240 Dp D N A PRI 0 6 - J A N - 1 9 9 5 
©EFIUITION Human i n s u l i n r e c e p t o r ( a l l e l e 2> c jene, exons 1 4 , 1 5 , 16 and 1 7 . 
A C C E S S I O N M2V930 M22986 M24639 
KEYWORDS A l u r e p e a t ; i n s u l i n r e c e p t o r . 
SOURCE Human IymohoDI a s t o i d c e l l l i n e or p e r i p h e r a l b l o o d l y m p h o c y t e UNA. 
ORGANISM homo s a p i e n s . . . . _. 
SCORES I n i t l : 549 I n i t n : 802 O p t : 703 




g b _ p r : n o ti)3 s e l e c t 
LOCWS H D M 0 S ? L £ C r 4 8 S £ bp DMA PR I 
D E F I N I T I O N Homo s a p i e n s P - s e l e c t i n CD&2 (GftMP) g e n e , 5 ' e n s and p r o m o t e r 
r e g i o n . 
A C C E S S I O N L 0 1 5 7 4 
K E Y W O K D S P-s<? I ? c t i n „ 
S O U R C E HOMIO s a p i e n s ( t i s s u e l i b r a r y ; C o l o n i c m u c o s a D M A ° . o , 
S C U R E S I n i t l : 2 6 4 l n i t n ' : 7 2 3 Opt 
7 0 . 0 4 i d e n t i t y i n 4 0 0 bp o v e r l a p 
6?<5 
F i g u r e 3 . 3 . I X , 
178 Alul 
116 Mae II 
107 XbaI 
94 SfaNI 
90 BspM I 
82 Acc I 
61 BceF I 
58 Fnu4H I 
58 Bbvl 
II H I I 
813 Bgll 
686 Tth111 I 867 Hindi 
682 Taql 8 1 7 N c o l 
284 EcoNI 
250 Stu I 
217 A v a l 
I I I 
649 Mbol 
637 Mmel 
628 Bsm I 
613 Gdi II 
U l l H 
807 NspCI 
807 Nsp7524I 
807 Nspl 1005 Dral 
773 Fau I 960 Msc I 
J I I L J L 
1133 
I 
N T G S 5 R V + U P 1137 b a s e pairs Unique S i tes 
F i g u r e 3.4.1, R e s t r i c t i o n m a p o f N T G + 5 sequenced r e g i o n . 
| 1 0 | 2 0 | 3 0 | 4 0 
1 G A T C A C G G G C G T T G G T G A A G G A T T G G C C C A A G A C G G G G T G 
8 1 C G T A G A C A A A C C T G C A T C T G T T A G T T T C T A G A T T T A C G T T 
1 6 1 C A C C C C C A G G T A T T G T C A G C T T A G G T T T T T C T C C T C T G T T 
2 4 1 T G A G G G A G G A G G C C T G T G A T A C A G T T C T C T C T G G A G T C T G 
3 2 1 G G G C C G G G G A A G G G C C C C G G T G A C T C C A G T G C A G G C C G G G 
4 0 1 A T T A T A T A G A A T A T A A T A T A T A A T A T T A T A T A G A A T A T A A 
4 8 1 G A A T A T A A T A T A T A A T A T T T T A T A G A A T A T A A T A T A T A A T 
5 6 1 A T A T A A T A T A T A G A A T A T A A T A T A T G A T A T T * * * C A A T A G 
6 4 1 A C T A G A G G G A A G A A T A A T A T A A A A C T T C C A A T A A T T T T T T 
7 2 1 A G T G G T G T G A T T G G C T C A C T G C A A C C T T C A C C T T C C A G G C 
8 0 1 C T A T G G G C A T G T G C C A C C A T G G C T G G C T A A T T T T A G T A T T 
8 8 1 T C T C A T G T T C A T A G G C T C A A G C A A T T A A C C C A C T C C A G C C 
9 6 1 G G C C A G G T T C T A G T A A T T G T A A T A T A G G A T T T G C T T A T G T 
1 0 4 1 T T C T G T T T T A T T A G A T G T A T T G A A A A C A G T G A T A T G G T C A 
1 1 2 1 G C C A A G G C A A G T G G A T C 
| 1 0 | 2 0 | 3 0 | 4 0 
| 5 0 | 6 0 I 7 0 | 8 0 
G A A T C T G G A A C C A C T T T G C T G C C G T A A T A C A G G G C C C C T G 8 0 
T C C A C G G A A A T T G C T C A C C A T G T C A A G A A T C T G T T T T A T G 1 6 0 
T T T A T T C C A G A G T T C T C T C G G G C T C C C T C T G T C A T G T T G C 2 4 0 
G A A C C T G A G C A A G G G T G G C A G T G G G A G G A A C C G C T T T A T A 3 2 0 
G A G C G A A G T C T G G G A G A A G G C C C A G A A T A T A A T A T A T A A T 4 0 0 
T A T A T A A T A T T T T A T A G A A T A T A A T A T A T A A T A T T T T A T A 4 8 0 
A T T T T A T A G A A T A T A A T A T A T A A T A T T T T A T A G A A T A T A T 5 6 0 
G A T A A G T T C T G C T G G C C G A G T G G A G T G G A A T G C A A G T C C A 6 4 0 
T T C G A G A C G A G G T C T T A T T C T G T C A C T C A G G C T G G A G T G C 7 2 0 
T C A A G C A A T C C T C C C G C C T C A G C C T C C T G A G T A T T T G G G A 8 0 0 
T T T T T C T A A A G A T G G G G T T T T G C T A T G T T G A C C A G G C T C G 8 8 0 
T C C C A A A G T G C T G G G A T T A T A G G C A T G A G C C A C C A T G A C T 9 6 0 
A T T T T T T A A A A A T G A G T G A T A G T G A G T A A C C A A T T A A G T A 1 0 4 0 
G G C A C G G T G G C T C A C G C C T G T A A C C C C A G C A C T T T G G G A G 1 1 2 0 
1 1 3 7 
| 5 0 | 6 0 | 7 0 | 8 0 




Sad PstI PstI EcoRI 
1 — — 1 1 
Sau3A 500 bp 
^^^^miiiHlllllilligMBWWHBHHBl 1 
500 bp 5t3^ 3A 
> < 
Sequenced Sequenced 
Figure 3.5, N T G + 5 sequenced regions. 
• NTG+5 was digested using the SacI/EcoRI double digest (see method 2.2.2.8), 
to check i f it possesses SacI or EcoRI sites, (see figure 3.6) 
Sua mrter 
23*13 Kb _ 
.2-03 *fc _ 
Mi0 
I I P 
P':::|: 
Figure 3.6, 2ul o f NTG+5 SacI, EcoRI, SacI/EcoRI digest on 1.2% Agarose gel. 
Digest results: 
Sacl^> 5.0 Kb 
EcoRI => 5.0 Kb 
SacI/EcoRI 2.5Kb (vector) + 2.3Kb (insert) 
Summary 
The NTG5 insert does not contain SacI or EcoRl sites, the only sites present in 
NTG+5 are those in the polylinker. 
















2,2 Kb Insert 
SacI EcoRI 
2.4 Kb Vector 
Figure 3.7, SacI/EcoRI digestion o f NTG+5 
• 10 different enzymes were used for digesting NTG+5 to identify the presence of 







Figure 3.8, 2\x\ o f each of the 1 0 d i f fe ren t digests o f NTG+5 on 1.2% Agarose gel 
4 9 
PstI e x c i s e s a f r a g m e n t o f 1 . 4 K b , Hindll {Hindi) e x c i s e s a f r a g m e n t o f 2 9 0 b p 
L o o k i n g a t t h e r e s t r i c t i o n m a p , t h e r e i s a Hindi s i t e a t 8 6 7 , t h e r e f o r e t h e t o t a l 
l e n g t h 1 1 3 7 - 8 6 7 = > 2 7 0 b p c o r r e s p o n d s w e l l w i t h t h e a b o v e d i g e s t . 
S u m m a r y - Hindll (Hindi) 
Hindll 
Hindi i EcoRI Hindll 
Sau3A i| 1 1 290 bp 
^ EcoRI Sau3A 
Hindll ) 




4.8Kb -r- Hindi 
j (Hindi!) 
Figure 3.9, Hindll digestion of NTG+5. 
S u m m a r y - PstI 
= > T h e Sau3A f r a g m e n t i n N T G + 5 i s a p p r o x i m a t e l y 2 . 2 K b f r o m t h e p r e v i o u s 
SacI/EcoRI d i g e s t s . 
= > W h e n N T G + 5 i s c u t w i t h PstI i t e x c i s e s a 1 . 4 K b f r a g m e n t , t h e r e f o r e : 
PstI 
PstI PstI 
San 3A J^TST^TTW^ ^  Sau 3A ^ 1 1 1.4Kb 
^y\.Pst! Sau 3A 
f 
- j - EcoRI > + 
V / PstI S San 3A ^**n**J 
S a c l ^ ^ \ ) Z 2.2 - 1.4= 0.8Kb 
[ 3.8Kb - j - PstI 
Figure 3.10, PstI digestion of N T G + 5 . 
5 0 
In order to make sub-clones of NTG+5 for sequencing the fol lowing was done: 
PstI EcoRI Sad 
500 bp Sau3A Sau3A 500 bp 
Sequenced Sequenced 
Digest NTG+5 with Pstlk SacI 
• 
SacI 
PstI PstI PstI 
f 
EcoRI 
Sau3A 500 bp 500 bp Sau3A 
> < > < 
Sequenced UP ^ Sequenced 
800 bp 1.4 Kb 
Figure 3 . 1 1 , Sequencing strategy for N T G + 5 sub-clones. 
The 80()bp and 1.4Kb bands were isolated from agarose gels using method 




Figure 3 . 1 2 , 100|al o f N T G + 5 Figure 3 . 1 3 , I O O l i I o f N T G + 5 F.s//digest 
SacJ/PstI digest on 1 .2% gel. lOOul o f Sacl/Pstl cut pBluescript on 1 .2% gel. 
The 800bp fragment was ligated into SacI/PstI cut pBluescript (see figure 
3.14): 
SacI 
2.9 Kb -T-Psfl 
pBluescript 
Figure 3.14, SacI/PstI cut pBluescript. 
=> Sequenced using the UP and homology search using the Daresbury database 
showed the fo l lowing (see figure 3.16.1 & I I for predicted restriction map and 
sequence: 
5 s c / r e v 
q b _ p r : n u m c o l r e p u 
LOCUS HUMCULREPU 8 0 1 DO ONA PR I 0 1 - N O V - 1 9 9 * . 
D E F I N I T I O N Human v a r i a b l e n u m b e r t a n d e m r e p e a t ( V N T R ) r e g i o n / a l l e l e 1 7 r U 3> 
t o c o l l a g e n t y p e I I ( C O L 2 A 1 ) g e n e . 
ACCESS I O N L 1 0 1 7 1 
kEYWORUS V N T R ; c o l l a g e n ; c o l l a g e n t y p e I I ; 
v a r i a b l e n u m b e r t a n d e m r e p e a t a l l e l e . . . . 
S C U T E S • I n i t l : 3 3*. I n i t n : 3 ^ 3 O p t : d 8 6 
70.5'-'. i d e n t i t y i n 6 6 1 b p o v e r l a p 
Figure 3.15.1, 
g b _ o r : h u m t c r o 
LOCUS HUMTCR6 6 8 4 9 7 3 bp UNA PR I 1 4 - J A N - 1 9 9 5 
J E F I N I T I O N Homo s a p i e n s ( c l o n e s : K 4 1 A , K. 3 S ^ K 2 6 / X 2 1 B , G54 , H 1 3 7 , H 1 8 , 
H l b / G 1 5 g a p , G 1 5 , X 1 A , A 2 7 , A 2 1 2 / A 1 4 , H 7 . 1 , H 1 2 . 1 8 , H 1 3 0 , A 1 6 , 
C 2 1 5 , G l , C 6 8 , C 2 1 , X l l , X6A/• C B G 1 / C B G 1 / C 2 9 g a p , a n d C 2 9 ) g e r m l i n i 
I - c e l l r e c e p t o r b e t a c h a i n , c o m p l e t e g e n e . 
A C C E S S I O N L 3 6 0 9 2 . . . 
SCORES I n i t l : 1 6 1 I n i t n : 3 8 8 O p t : 5 8 5 
6 3 . 7 ! : i d e n t i t y i n 63 0 bp o v e r l a p 
Figure 3.15.II, 
52 
5 s c / r e v 
y b _ p r : h u m i f n D 2 a 
LOCUS H U M I F N B 2 A 5 4 4 bp UNA PR I 
J E F I M I T I O N H u m a n i n t e r l e u k i n 6 ( I L 6 ) g e n e , 3 " f l a n k . 
A C C E S S I O N J 0 3 0 4 9 
KEYWORDS i n t e r f e r o n - b e t a - 2 ; i n t e r l e u k i n 6 . 
SOURCE H u m a n U N A . 
O R G A N I S M Homo s a p i e n s 
S C O R E S 
0 8 - N O V - 1 9 9 4 
I n i t 1 : 2 1 2 l n i t n : 3 4 2 O p t 
7 2 . 6 i d e n t i t y i n 4 9 3 op o v e r l a p 
7 4 4 
Figure 3.15.111, 
5 s c 
j b _ D r : h s c o l i i 2 
LOCUS H S C O L I 1 2 2 4 6 1 bp D NA PR I 0 4 - N O V - 1 9 9 4 
D E F I N I T I O N H u m a n a l p h a 1 ( 1 1 ) c o l l a g e n g e n e 3 ' u n t r a n s l a t e d r e g i o n . 
A C C E S S I O N X 0 2 6 7 0 
KEYWORDS AT r i c h r e g i o n ; c o l l a g e n ; c o l l a g e n a l p h a 1 t y p e I I ; 
c o l l a g e n t y o e I I ; t a n d e m r e p e a t . 
SOURCE h u m a n . . • • 
SCORES I n i t l : 1 5 3 I n i t n : 2 2 1 O p t 8 1 4 









12 Ban I 
II Mi l l I 
I I 
5 .80().i ip 739 base pairs Unique Sites 
Figure 3. 16.1, Restr ic t ion map for 800bp SacI/PstI sub-clone o f N T G + 5 
53 
I 10 I 20 I 30 | 40 
1 GAAAGTATCC AGGCACCCCC GAGGGTGCAC ACACCCAGGG 
81 TCTTGGGGAC TGGTTCTACC GAAACATATA TACATATATG 
161 TATATATATA CACGTGTATA TATATATATA TAACAGATAA 
241 TATATTTTGT ATTCTATATA TTATATACTA TGTATTCTAT 
321 ATTCTATATT CTATATTATA T T C T A T A T T C TATAGAATAT 
401 TATTCTATAT TCTATAGAAT ATTCTATATT ATATTCTATA 
481 CTATATAATA TTATATATTA T A T T C T A T A T ATTATATATT 
561 TTATATTCTA TATATTATAT ATTAATATTC TATATATTAT 
641 TTATATATTA T A T T C T A T A T ATTATATATT ATATTCTATA 
721 TCCCATAAAA TATTATATA 
| 10 | 20 | 30 | 40 
| 50 | 60 | 70 | 80 
CTAGGAGACC TCAGGTTTAT A C G T C T C T T T C T T T T C T C T T 80 
ATATATACAC ACACGTGTAT ATATCTCATA TATATATATA 160 
CGTATAATTA TAATTATATT ATCTGTAATA TATAATTATA 240 
ATAATATATA TTATGTATTC TATATAATAT TATATATTAT 320 
TCTATATTAT ATTCTATATT CTATAGAATA T T C T A T A T T A 400 
TTATATTCTA TA TATTCTAT ATAATATTAT AT ATTATATT 480 
ATATTCTATA TATTATATAT T A T A T T C T A T ATATTATATA 560 
ATATTATATT CCTATATATT ATATATTATA TTCCTATATA 640 
TATTATATAT TATATTCTAA TAAAATATTA TATATTAATA 720 
7 3 9 
| 50 | 60 | 70 | 80 
Figure 3.16.11, D N A sequence for 800bp SacI/PstI sub-clone of N T G + 5 . 
• The 1.4 Kb PstI fragment was ligated into PstI cut pBluescript: 
PstI 
pBluescript 
Figure 3.17, PstI cut pBluescript. 
• To determine the orientation o f the fragment, l u l o f 1.4Kb PstI was digested 
wi th Hindi/, as the PstI fragment can ligate into the vector in either orientation 




HmdU Hmdll PstI SauSA 
PstI 
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2 9 0 b p 
Would sequence this clone 






Would sequence this clone 
with the UP to get new-
sequence 
; '<Kb 
Figure 3.18, Possible recombinants. 
» Z 3 
Figure 3.19, 2uJ of 1.4Kb /\sr7 sub-clone on 0.8% Agarose gel. 
sub-clones o f 1.4Kb PstI were tested 
1 had 4Kb + 290bp 
2 had 1.1 I Kb t- 3.2Kb 
The first sub-clone (4Kb + 290bp) was sequenced using RV. The homology search 
shows the f o l l o w i n g (see figure 3.20 I & I I for predicted restriction map and 
sequence): 
S s c ^ / r e v 
Q b _ D r : h s r b 2 p l 3 0 
LOCUS H S K B 2 P 1 3 U 3 2 4 9 bp UNA PR I It-MAR-
u l E F I N I T I OtJ ri.sapiens mRHA f o r R o 2 / p l 3 0 p r o t e i n 
A C C E S S I O N X 7 / . 5 V 4 
N I 0 g 3 V 7 1 4 7 
KE VUORUS E1A b i n d i n g p r o t e i n ! r e t i n o b l a s t o m a - a s s o c i a t e d p r o t e i n . 
SOURCE n u m a n . 
SCORES I n i t l : 6 8 I n i t n : 1 1 1 O p t : 1 1 2 
S 5 . 7 ! ; i d e n t i t y i n 2 1 9 bp o v e r l a p 
Figure 3.20.1, 
5 s c 3 
g b _ D r : n u m c i l 3 o a 
LOCUS HUMCl»3oA 2 5 6 1 OP UNA PR I U 3 - M A R - 1 V 9 3 
D t E M I I I UN H u m a n a n t i j e n CD J 6 qene<- a l t e r n a t e e * 0 n s 2 a a n d 2 b a n d e x o n 3 . 
ACCESS I O N L 0 6 3 1*0 
N I D g 6 9 l 7 6 2 
KE rVuR,DS A l u r e p e a t ; a n t i g e n CO 3 6 . 
SOURCE Homo s a o i e n s ( t i s s u e l i b r a r y : E^ f t L O OMA. . . 
SCORES [ n i l ! : 6 9 I n i t n : 1 1 2 O p t : 6 9 
7 4 - 7 . * i d e * t i t i n I P b p o v e r l a p 
Figure 3 .20 . I I , 
5 6 
5 s c 3 / r e v 
g b _ o r : s6 7 1 7 ! 
LOCUS 
D E F I N I T I ON 
A C C E S S I O N 
M I D 
S 6 7 1 7 1 3 4 4 8 bp mHNA r^RI 0 4 - F t d - l V ° < » 
R b r - 2 = r e t i n o b l a s t o m a s u s c e p t i b i l i t y g e n e [ h u m a n / H e L a S3 s u s p e n s i o n 
c e U s <• mRN A , 3A 4<j n t J . 
S 6 7 1 7 1 
g < i 5 3 1 3 1 
SCURES I n i t l : 6 3 I n i t n : 1 1 1 O p t : 1 1 2 
5 5 . 7 r; i d e n t i t y i n 2 1 9 bp o v e r l a p 
Figure 3 .20 . I l l , 
<j b _p r : n s ;i c q i l 
LOCUS H S H C G I I 3 6 4 2 b p R.NA P R l 1 3 - A U ' 3 - 1 V ; 
D E r l K l l T l O N H . s a p i e n s h C G I I H IRNA. 
A C C E S S I O N X f t l O O l 
NlD 5 S 3 L 4 0 7 
K E W O R D S H C 6 I I ^ e n e . 
SOoR.CE human. . . . 
S C O K E S I n i t l : 57 I n i t n : 1 3 1 O p t : 7 8 
5 3 . 7 # i d e n t i t y i n 2 3 i bp o v e r l a p 
Figure 3 .20 . IV, 
5 s c > 
q b _ p r : n s I 2 5 3 L 2 
LOCUS M S L ^ S G l ? 3 7 1 5 3 b p DNA PR 1 0 5 - O C T - 1 9 9 5 
D E F I N I T I O N H u m a n ONA s e q u e n c e f r o m c o s ^ i d L 2 5 U 1 2 , H u n t i n g t o n ' s O i s - a s e R - i o n , 
C h r o m o s o m e 4 p l 6 . 3 . 
A ,CCES5iON 254336 
M I D <$U>lS'.9& 
KEYV/ORoS V b L c ^ - 3 - . . . 
SCURES I n i t l : 115 I n i t n : U 5 O p t : 
i d e n t i t y i n 12 0 bp o v e r l a p 
1 2 4 
Figure 3 .20.V, 
57 
153 Xcm I 318 NspC 1 
150 Fok1 318 Nsp7524 I 
137 ScrFI 318 NspI 
137 EcoR II 275 Alu I 
137 DsaV 261 Bsp1286l 
137 BstNl 261 Ban II 339 Xmn I 
112 AccI 212 Rsa 1 316 Nsi I 
101 Hae III 189 RIM I 274 Pvu II 465 SlaN I 
39 BsmA I 137BstKI 212Csp6l 302 Hga 1 414Sspl 
33 Xba I 100 Hae I 189BsiYI 274 NspB II 359 Mae III 451 Mse I 
I I 1 I I II I I 1 1 1 II 1 1 1 I I 
1 1 
5scr2 588 base pairs Unique Sites 
Figure 3.2 1.1, Restriction map of 1.4Kb PstI sub-clone of NT G +5 . 
| 10 | 20 I 30 | 40 I 50 | 60 | 70 | 80 
l CTCAGAGAGC ATGGGCTGTT TGAAAGGCAA TTTCTAGAGT CTCAGTTTAG ACACAGACTC GTTCCTAAAG AAAGCCTTTT 80 
81 C T C C T A G T T T ACAAGCAGAA GGCCAGTTCT T G T C T A C T C C CCTCCCCCAG AGTCCTCCAG GAAGCAAAAC ATCCATTGGA 160 
161 ATACTGGTGT AGGGCAAGAA ACCTGATTCC AATGATTGGG AGCAAGTGCT TGTACAAACC ACAGGGCTTC C A A T T C T T T G 240 
241 CTTTCAACAA AATTGAAGAA GGGCTCACAT TGTCAGCTGA TAAATTATAC AAAATTTTTT GGACGCTAGG TCTGTATGCA 320 
321 TGTTTTGGCA TATAATATGA AAGAGTTCAG ATAAGCGAGT AACTGAAATA TAACCAGACA C T T G C C A T T T C T A T C C A C T T 400 
401 GTCTATACCA ACCAATATTT ATCAGGGACT T C T G C C C A T A CCAAATTCTC TTAAAAATAA AATTGATGCC GAATCCTGTT 480 
481 C T C T T T C A A T C C C A T T C G T A AATAATACTT ACCCATGAAT ACATGAAAAA CAGTCCCATT TTTCCCAGTA AGAAATTATA 560 
561 G A T T A T T T C C C T C C A G T T T T A C T T C T T C 588 
| 10 | 20 | 30 | 40 I 50 | 60 | 70 | 80 
Figure 3.21.11, DNA sequence for 1.4Kb PstI sub-clone of NT G +5 . 
NTG+8 
• Insert size approximately 956bp. 
• Sequenced ini t ia l ly using RV-UP figure 3.24, (see figure 3.23.1 & I I for 
predicted restriction map and sequence). 
• Homology search using the Daresbury database shows the fo l lowing : 
58 
8 r 
j b _ p r : hs mhc a pg 
L O C U S H S M H C A P G 6 6 1 0 9 bp O N A P R I 1 6 - N O V - 1 9 9 4 
D E F I N I T I O N H s a p i e n s g e n e s T A P 1 , T AP 2 / L M P 2 / LHP 7 a n d D O B . 
A C C E S S I O N X 6 6 4 0 1 S 5 7 5 2 8 
K E Y W O R D S DOb g e n e . L F I P I g e n e ; LMP7 g e n e ; 
m a j o r h i s t o c o m p a t i b i l i t y c o m p l e x c l a s s I I ; t a p l g e n e ; t a p 2 g e n e , 
S O U R C E h u m a n . . „ . 
S C O R E S I n l t l : 72 I n i t n ; 1 5 4 O p t : 74 
7 9 . 3 5 I d e n t i t y i n 29 bp o v e r l a p 
Figure 3.22.1, 
g b _ p r : h s t c r bv 
L O C U S 
D E F I N I T I O N 
A C C E S S I O N 
KEYWORDS 
S O U R C E 
ORGAN I S M 
H S T C R B V 7 7 7 4 3 bp DNA P R I 
Human V b e t a T - c e t l r e c e p t o r ( T C R B V ) g e n e l o c u s . 
U 0 3 1 1 5 
« 
h u m a n . 
Homo s a p i e n s . . . 
2 0 - A P R - 1 9 9 4 
S C O R E S I n i t l : 71 I n i t n : 2 0 6 O p t : 1 4 4 
5 7 . 3 5 ; i d e n t i t y i n 2 3 9 bp o v e r l a p 
Figure 3.22.II , 
8 r 
g b _ p r : h u m v c a m a 
L O C U S 
O E F I N I T I O N 
A C C E S S I O N 
KEYWORDS 
S O U R C E 
O R G A N I S M 
HUHVCAHA 2 3 9 6 bp DNA ' P R I 1 4 - J A N - 1 9 9 5 
Human v a s c u l a r - c e l l a d h e s i o n m o l e c u l e - 1 ( V C A H 1 ) g e n e / e x o n 1 . 
H 9 2 4 3 1 
v a s c u i a r c e l l a d h e s i o n m o l e c u l e - 1 . 
Homo s a p i e n s DNA. 
Homo s a p i e n s . . . 
S C O R E S I n i t l : 6 2 I n i t n : 1 3 8 O p t : 
6 1 . 5 5 i d e n t i t y i n 1 1 7 bp o v e r l a p 
92 
Figure 3 .22 . I l l , 
59 
Cjb _o r : n s r D 2 ;i I 3 J 
LOCUS H S R 3 2 P 1 3 u 3 2 4 9 bp R N A PR I 1 4 - M A : ? - 1 V ? ; 
D E F I N I T I O N H . s a p i e n s mflNA f o r R b 2 / p l 3 U p r o t e i n . 
A C C F S 5 i n N V 7 i | 5 < H 
K I O g l 9 7 U 7 
K E / V O T D S E l A b i n d i n g p r o t e i n : r e t i n o b I a s t o p j - a s s o c i a t e 1 p r o t e i n . 
SOURCE h u m a n . . . . 
SCOPES I n i t l : 6 8 I n i t n : 1 1 1 O p t : 1 1 2 
5 5 . 7 * i d e n t i t y i n 2 1 9 b p o v e r l a p 
Figure 3 .22.IV, 
g b _ p r : hs u 0 4 6 3 6 
LOCUS 
O E F I N I T I O N 
H S U 0 4 6 3 6 ° 4 5 3 bp UNA 
H u m a n c y c l o o x y g e n a s e - 2 ( h C o x - 2 ) g e n e 
P R I 2 1 
, c o m p l e t e c d s . 
- D E C - 1 9 9 4 
ACCESS I O N U 0 4 6 3 6 
KEYWORDS . 
SOURCE n u r a a n . 
ORGAN I S M Homo s a p i e n s • . • 
SCORES I n i t l : 8 8 I n i t n : 1 4 6 O p t : 
5 4 . 1 ! ; i d e n t i t y i n 4 4 2 bp o v e r l a p 
1 2 0 
Figure 3.22.V, 
g b _ o r : h u m v i t d b p 
LOCUS 
D E F I N I T I O N 
ACCESS I O N 
H U H V I T D B P 5 5 1 3 6 bp DNA 
H u m a n v i t a m i n D - o i n d i n g p r o t e i n ( G O 
L 1 Q 6 4 1 L 1 0 6 4 2 
P R I 27 
g e n e / c o m p l e t e 
- J A N -
c d s . 
1 9 9 5 
KEYWORDS 
SOURCE 
g r o u p - s p e c i f i c c o m p o n e n t ; v i t a m i n D -
Homo s a p i e n s D N A . 
o i n d i n g p r o t e i n . 
ORGAN I S M Homo s a p i e n s . . . 
SCORES I n i t l : 7 1 I n i t n : 1 4 3 O p t : 
6 1 . 9 ~ i d e n t i t y i n 10 5 b p o v e r l a p 
9*. 
Figure 3 .22 .VI , 
6 0 
ar 
9 b . p r : h u m r e t b l a s 
LOCUS 
O E F I N I T I O N 
ACCESS ION 
KEYWORDS 
2 3 - N O V - 1 9 9 4 
2 7 , c o m p I e t e 
HUMRETBLAS 1 8 0 3 8 8 D P DNA PR I 
H u m a n r e t i n o b l a s t o m a s u s c e p t i b i l i t y g e n e e x o n s 1 
L l l V j . u 
n u c i e a r p r o t e i n ! ' r e c e s s i v e o n c o g e n e ? r e t i n o b l a s t o m a g e n e ; 
r e t i n o b l a s t o m a p r o t e i n ; r e t i n o b l a s t o m a s u s c e p t i b i l i t y ; 
t u m o r s u p r e s s o r g e n e . . . . 
c d s . 
SCORES I n i t l : 7 6 I n i t n : 1 6 1 O p t : 1 1 7 
5 2 . 6 S ; i d e n t i t y i n 4 4 1 b p o v e r l a p 
Figure 3 .22 .VII , 
g b _ p r : h u m p t g s 2 
LOCUS HUHPTGS2 1 0 9 9 7 bp DNA PR I 2 1 - J U L - 1 9 9 4 
D E F I N I T I O N H u m a r P T 6 S 2 g e n e f o r p r o s t a g l a n d i n e n d o p e r o x i d e s y n t h a s e - 2 . 
A C C E S S I O N D 2 8 2 3 5 
KEYWORDS p r o s t a g l a n d i n e n d o p e r o x i a e s y n t h a s e - 2 . 
SOURCE Homo s a p i e n s ( l i b r a r y : E M B L 3 ) J a p a n e s e p e r i p h e r a l b l o o d D N A . 
O R G A N I S M Homo s a p i e n s . . . 
SCORES I n i t l : 8 8 I n i t n : 1 4 6 O p t : 1 2 0 
5 4 . 1 £ i d e n t i t y i n 4 4 2 b p o v e r l a p 
Figure 3 . 2 2 . V I I I , 
y b _ p r : h u m f g l b t k 
LOCUS 
D E F I N I T I O N 
A C C E S S I O N 
KEYWORDS 
HUMFGLBTK 6 9 3 6 3 bp DNA PR I 0 7 - J U N - 1 9 9 5 
H u m a n f t p - 3 g e n e , e x o n 1 ; a I p h a - D - g a I a c t o s i d a s e A ( G L A ) g e n e / e x o n s 
1 - 7 ; L 4 4 L g e n e / e x o n s 1 - 5 . ' B r u t o n ' s t y r o s i n e k i n a s e ( B T K ) gene, 
e x o n s 1 - 1 8 . 
L 3 5 2 6 5 
B r u t o n ' s t y r o s i n e k i n a s e ; a I p h a - D - g a I a c t o s i d a s e A . • . . 
SCORES I n i t l : 60 I n i t n : 1 3 2 O p t : 82 
5 4 . 6 : ; i d e n t i t y i n 18 3 bp o v e r l a p 
Figure 3 .22 . IX, 
61 
568 Mspl 
568 Hpa II 
567 Xma I 
567 Smal 
567 AvaI 
537 Sea I 
530 Fnu4HI 730 Avail 916 Mae III 
504 Hael 715 Tfi I 870 Mril I 
393 RIM I 530 Bbv I 683 Pie I 845 Xba I 
290 Sfe I 496 EcoN I 649 Nsi I 826 Ase I 952 Alw I 
J I II II l I I U L I I I L 
NT(1S 8 R + U 956 base pairs Unique Sites 
Figure 3.23.1, Restriction map of N T G + 8 . 
I 10 | 20 I 30 I 40 I 50 | 60 I 70 | 80 
1 G A T C A T T T T G AAATCTTTGA C C T T T A T A T T TTAATGAATA AAATATTAGT AGTTATTAGT ATAAAATAAT T T A T G T C T T T 80 
81 TGGACTTAGC ATCCAGTATT T C T T T T T T A A TAAAGAAAAT A A T T A T T C T C TTGCAATATA C T G T G T T T A C CTGGGTTTTG 160 
161 AAAAGTGATG TTTCCTAATA TGAGAAAGCC A T T T A C A T T T TTAAATCTAC AAAGGCAAAT GGAATGGTAC TAAATTATTT 240 
241 ATATAATAAT GTTTAGATGG TGGCCCTTAT A A C A T T C T T T C T A T A C T T C C TACAGAGTTG GGGATATGCA ATCCTGGAAT 320 
321 ATTTCTGGGA GCTAATCCTT TAGCTTGATG AATGAAACAA GACTTTTAAA TAAAATTAAA CTTTCAAATT ATCCAGGTAA 400 
401 TGGGCCTGTC TTTTAATTCA ATGGATATGG AGCATAATGA A T T A T C C C C T GTtCATTGGG TAATAAGTTC T C A T T * * * * * 480 
481 + * * * * * » * « A TGTCCCCTAG TAAAGGCCAT GAACTCATCC A T T T T T A T G G CTGCATAGTA C T C C C C T G G T GTATAATGAA 560 
561 CCCTGACCCG GGAAAGGCCG AGATTAACTA AGCCTGTTTG CCATGGACAG CAATGGGGTT GCTAGAACAT TAGCTGTGTG 640 
641 GAACAATTAT GCATTTACCT TTGGGCATAA TACAATGCAA T T G A C T C T C C ATATTCATGG GTTCTGCATC CACCGATTCA 720 
721 AACAACTGTG GACCAAAATT GTCAGAAAAA ACAATACAAT GATAACAAAT GATACAAATA AAAAACAACA TGGTATACCA 800 
801 ACTATTTACA TAGCATTTAC ATCGTATTAA TTGTTATTAA GTAATCTAGA GATGATTTAA AGTATATAGG AGGATGTGTG 880 
881 TAGGTTATAT GCAAATACTA C A C T A T T T T A TACCAGTAAC TTGAGCATCC ATGGATTTTG GTATACAAGG GGGATC 956 
I 10 | 20 I 30 I 40 I 50 I 60 I 70 I 80 
















Figure 3.24, Sequenced region of NTG+8. 
NTG + 8 was digested using the SacI/EcoRI double digest (see method 2.2.2.8), 
to check i f it possesses SacI or EcoRI sites. 
SacI => 5.0 Kb 
EcoRI ^ 5.0 Kb 
SacI/EcoRI => 2.9Kb (vector) + 2.8Kb (insert) 
62 
Summary 
The NTG8 insert does not contain Sad or EcoRI sites, the only sites present in 
NTG+8 are those in the polylinker. 
Sad EcoRI Sad 
5 Kb 
t a d / Sad Sau3A Sau3A Sau3A Sau3A 
EcoRI Sad 
EcoRI Sad EcoRI EcoRI 
5 Kb 5 Kb 
Sau3A Sau3A \ 
VcoRT\ 
Sad/ 
EcoRI Sad EcoRI 
2.8 Kb Insert 
Sau3A Sau3A 
Sad EcoRI 
2.9 Kb Vector 
Figure 3.25, EcoRI/SacI digestion of NTG+8. 
• 10 different enzymes were used for digesting NTG+8 to identify presence of 
restriction sites (see method 2.2.2.8), (see figure 3.26). 
I 5 I 3 i mmar "» eg £ i «o a x v w 1 1 t i 1 
Figure 3.26, 2u.l of each of the 10 different digest of NTG+8 on 1.2% Agarose gel. 
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Hindll excises a fragment of 1.4Kb. 
2.8 Kb 




Figure 3.27, Fragments of NTG+8. 
Summary - Hindll 
Hindll Sau3A 
HindU EcoRI Hmdll 
Hindll 
Sau3A 
Figure 3.28, Products of Hindll digestion of NTG+8. 
In order to make sub-clones of NTG+8 for sequencing the following was done 
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1.4 K b 
EcoR! 
Figure 3.29, Sub-cloning strategy for NTG+8. 
=> The 1.4Kb fragment and 700bp fragment were isolated from agarose gels using 






Figure 3.30, 150ul of NTG+8 Sacl/Hindll digest on 2% agarose gel. 
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=> The 700bp fragment was ligated into Sacl/Hindll cut pBluescript: 
Sad 
i — Hindll 
pBluescript 
Figure 3.3 1, Sacl/Hindll cut pBluescript. 
Sequenced using the UP. Homology search using the Daresbury database 
showed the following (see figure 3.33.1 & II for predicted restriction map and 
sequence): 
g b _ p r : h u m r e t b l a s 
LOCUS H U M R E T B L A S 1 8 0 3 8 8 b p DNA P R I 2 3 - N 0 V - 1 9 9 4 
D E F I N I T I O N H u m a n r e t i n o o I a s t o ma s u s c e p t i b i l i t y g e n e e x o n s 1-27, c o i t i p l e t e c d s . 
A C C E S S I O N L 1 1 9 1 0 
(CEYVIOROS n u c l e a r p r o t e i n . ' r e c e s s i v e o n c o g e n e . " r e t i n o b l a s t o m a g e n e ; 
r e t i n o b l a s t o m a p r o t e i n ; r e t i n o b l a s t o m a s u s c e p t i b i l i t y ; 
t u m o r s u p r e s s o r g e n e . . . . 
SCORES I n i t l : 1 1 8 I n i t n : 1 9 2 O p t 1 7 4 
8 6 . 4 S i d e n t i t y i n 6 6 b p o v e r l a p 
Figure 3.32.1, 
j b _ p r : h u m t c r a d c v 
LOCUS 
i ) E F I N I T I ON 
A C C E S S I O N 
KEYWORDS 
HUMTCRADCV 9 7 6 3 4 op 1>NA P R I 1 3 - J A N - 1 9 9 5 
H u m a n T c r - C - d e l t a g e n e , e x o n s 1 - 4 ; T c r - V - d e l t a g e n e , e x o n s 1 - 2 , 
T - c e l l r e c e p t o r a l p h a ( T c r - a l o n a ) g e n e , J 1 - J 6 1 s e g m e n t s ; a n d 
T c r - C - a l p h a g e n e , e x o n s 1 = 4 . 
M 9 4 0 8 1 
T - c e l l r e c e p t o r C - a l p h a ; T - c e t l r e c e p t o r C = d e l t a ; . . . 
iCORES I n i t l : 1 1 0 I n i t n : 1 4 8 O p t : 1 3 8 
8 4 . 9 % i d e n t i t y i n 53 b p o v e r l a p 
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3 b _ p r : h s p 5 3 g 
LOCUS H S P 5 3 G 2 0 3 0 3 bp ONA P R I 2 3 - A P R = 1 9 9 2 
O E F I N I T I ON H u m a n p 5 3 g e n e f o r t r a n s f o r m a t i o n r e l a t e a p r o t e i n p5 3 ( a l s o c a l l e 
t r a n s f o r m a t i o n - a s s o c i a t e d p r o t e i n p 5 3 , c e l l u l a r t u m o r a n t i g e n p 5 i 
a n d n o n - v i r a l t u m o u r a n t i g e n p 5 3 ) . 
A C C E S S I O N X 5 4 1 5 6 
KE YWOROS a n t i - o n c o g e n e t c e l l c y c l e c o n t r o l ; g r o w t h s u p p r e s s o r ; " " • 
o C O R c S I n i t l : 1 1 1 I n i t n : 1 4 8 O p t : 2 3 2 
6 6 . 0 i d e n t i t y i n 2 0 3 o p o v e r l a p 
Figure 3.32 I I I , 
g b _ p r : h s x l l g 
LOCUS H S X 1 1 G 2 8 6 4 bp ONA 
J E F I N I T I O N H . s a p i e n s x l l g e n e , p r o m o t e r r e g i o n , 
A C C E S S I O N 7 3 2 6 7 6 
KEYWORDS x l l g e n e ; x l l p r o t e i n . 
SOURCE h u m a n . 
O R G A N I S M Homo s a p i e n s . . . 
PR I 0 8 - O C T - 1 9 9 4 
SCORES I n i t l : 2 0 4 I n i t n : 3 3 2 O p t : 4 1 9 
7 4 . 7 ! ; i d e n t i t y i n 2 2 1 o p o v e r l a p 
Figure 3 .32 . IV, 
j b _ p r : h u m t p a 
LOCUS 
D E F I N I T I O N 
A C C E S S I O N 
KEYWORDS 
SOURCE 
HUMTPA 3 6 5 9 4 b p ONA P R I 
H u m a n t i s s u e p l a s m i n o g e n a c t i v a t o r ( t - P A ) 
K 0 3 0 2 1 
A l u r e p e a t ; (Cpn l r e p e t i t i v e s e q u e n c e 
t i s s u e p l a s m i n o g e n a c t i v a t o r . 
H u m a n f e t a l l i v e r , ON A l i b r a r y o f T . M a n i a t i s , 
g e n e , 
r e p e a t 
1 4 - J A N - 1 9 9 5 
c o u p l e t e c d s . 
r e g i o n . 
m u l t i p l e c l o n e s . 
SCORES I n i t l : 1 6 9 I n i t n : 3 2 3 O p t : 5 2 9 
7 6 . 9 : : i d e n t i t y i n 2 4 2 b p o v e r l a p 
Figure 3.32.V, 
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g b _ p r : h u m a f p 
LOCUS 
D E F I N I T I O N 
ACCESS I O N 
KEYWOROS 
SOURCE 
ORGAN I S M 
HUMAFP 2 7 5 5 3 b p UNA PR I 
H u m a n a I p h a - f e t o p r o t e i n g e n e , c o m p l e t e c d s . 
M 1 6 1 1 0 
a l p h a " f e t o p r o t e i n , 
h u m a n . 
Homo s a p i e n s . . . 
2 6 - M A Y - 1 9 9 5 
SCORES I n i t l : 1 0 1 I n i t n : 1 3 8 O p t : 1 8 4 
5 5 , 5 ! : i d e n t i t y i n 4 8 3 b p o v e r l a p 
Figure 3 .32 .VI , 
j b _ p r : h n m t c r b - 2 
C o n t i n u a t i o n o f HUMTCRB f r o m b a s e 3 5 0 0 0 1 ( L 3 6 0 V 2 Homo s a p i e n s ( c l o n e s : K 4 1 A , 
K 3 5 , K 2 6 , K 5 6 , X 2 1 B , 6 5 4 / H 1 3 7 / H 1 8 , H l S / G 1 5 g a p , G 1 5 , X 1 A , A 2 7 , A 2 1 2 , A 1 4 , 
H 7 . 1 , H 1 2 . 1 8 / H 1 3 0 , A 1 6 , C 2 1 5 , G l , C 6 8 , C 2 1 , X l l , X 6 A , C B G 1 , C B G 1 / C 2 9 g a p , a n d 
C 2 9 ) g e r m l i n e T --€-e-l 
SCORES I n i t l : 2 9 2 I n i t n : 4 7 2 O p t : 5 0 9 
7 1 . 1 5 ; i d e n t i t y i n 28 4 bp o v e r l a p 
Figure 3 .32 .VII , 
43 Sau96l 
43 Hae III 
239 Rsa I 
239 Csp6I 
238 Sea I 
186 Ddel 
171 Alul 314 Gsu I 
536 HgaI 
457 Mbo II 
412 B s r l 535 Aha II 
J I « 
670 Rmal 
669 Sty I 
669 Avrll 
J 
753 BsiY I 
8 U P S H 771 b a s e pairs Unique Si tes 
Figure 3.33.1, Restriction map for 700bp Sacl/Hindll sub-clone ( N T G + 8 ) . 
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I 10 I 20 | 30 | 40 
1 CTACAAAAAA AGCCAAACTG ACAGTATTAC TGAATAAGGA 
8 1 GGTATGACAC AACTTACCCT AACTATAAAG ACCCTAAATT 
161 TTTCACTTTT AGCTTTTTTA TTTCTCTCAG AATAAAAAGT 
2 4 1 ACTACAATGA CAGCACTTTT CAAGAAAAGA CTTTTTTCTC 
32 1 AATAATGAGT AAATAAAAAC ATAAGTATGT GGGTAATTAG 
4 0 1 ATGTATATTT CACTGGCTTT TCAATGCCAA CAATCATATT 
4 8 1 TGTGAACCTG AAAAGTAATC ACCACTTGGT AGTGACAATA 
5 6 1 TACATTTGCA GTTAAATTTG AAAACCCATG ATGTTTAATA 
6 4 1 TTTTAGAATT TAAGATAGAA CTAAAATACC TAGGGATAAT 
7 2 1 GTATTATAAA TTAAGAATGA AAACTTATTA CCCCATGAAC 
| 10 I 20 | 30 | 4 0 
I 50 | 60 | 70 
AAGGCCCAAA GAGACAAAAT ACTTTTTATT 
ACCAAGATGG GTGCTTATAA TATGGAGAGT 
GTATAAGGAG TTGATAAAGA AGTTGATACT 
TCTTACAAAT ATCATGTTAG CAGTATTTGT 
TGTAGTTTCT TAAATAAATG AGTTAGGCAA 
CTTTATAAGG CACAGAGAAG ATTTTTCTAA 
TGGATAGGGT GAAGGGCGTC ACCACGAAGC 
CATATAGTAA TAAAGAATAC TTCCTCCTGT 
GATATGACTA CCAAAAATTA AAAATTAAAG 
AGGGGATAAT T 
| 5 0 | 60 | 70 
| 8 0 
TTGTAACCTC 8 0 
TACAAAGTCA 160 
ATAAGTTAGT 2 4 0 
TTTCTCCAGA 3 2 0 
CAGGCTAATA 4 0 0 
AGAATAAGTA 4 8 0 
AATGAAAAGA 5 6 0 
CTCAAAATTA 64 0 
GATATTTGGA 72 0 
7 7 1 
I 80 
The 
Figure 3.33.II, DN A sequence for 700bp Sacl/HmdU sub-clone (NTG+8) . 




Figure 3.34, Hindll cut pBluescript. 
And sequenced using RV (see figure 3.27). 
The same procedure was used for the following NTGs: 
NTG+13 
Sad 








Figure 3.35, NTG+13 sequenced region. 
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=> Homology search shows the following (see figure 3.37.1 & II for predicted 
restriction map and sequence): 
I 3 r / r e v 
g b _ p r : h u m r a g l 
L O C U S H ' J f ^ A G l 6 5' .5 DO mR.'JA PR I O S - J A N - 1 9 9 5 
D E F I N I r i C N H U * a n r e c o m b i n a t i o n a c t i v a t i n g p r o t e i n ( R A G - 1 ) g e n e / c o m p l e t e c o s . 
A C C E S S I O N M 2 9 4 74 
K E Yv/JRuS r e c o m b i n a t i o n a c t i v a t i n g p r o t e i n . 
SOURCE H u i n a n p r e - B c e l l , l i n e NAL116 , c ON A t o mRNA / c l o n e H3 6 . 
ORGAN I S H Homo s a p i e r c s • • « 
S C O l c S I n i t V : 64 I n i t n : 1 0 5 Op t : 75 
5 5 . 0 ^ i d e n t i t y i n 2 4 9 t i p o v e r l a p 
Figure 3.36.1, 
9fa_p r : h u n i d s 
L O C U S HUMDS 2 2 5 7 3 b p SNA P R I 2 2 - K A R - 1 9 9 5 
D E F I N I T I O N H u m a n g e n e f o r d i h y d r o l i p o a n i d e s u c c i n y l t r a n s t e r a s e , c o m p l e t e c d s 
l e x o n 1 - 1 5 ) . 
A C C E S S I O N 0 2 6 5 3 5 
o i n y o r o l i p o a r , i a e s u c c i n y l t r u n s t e n s e . 
n o m o s a p i e n s ( l i o r a r y : l a m o c f a E M D L 3 ) o e r i p n e r a l o l o o c i c e l l s U N A , 
K E Y W O R J S 
SOURCE 
SCORES I n i t l : 3 7 3 l m t n : 5 1 4 O p t : 5 1 4 
6 8 . 5 X I d e n t i t y i n 3 5 2 bp o v e r l a p 
Figure 3 .36.II , 
g b _ p r : h s c s f l p o 
LOCUS 
DE F I N I T I ON 
ACCESS I OH 
K E Y W O R D S 
SCORES 
H S C S F 1 P 0 3 5 1 0 0 bp DNA P ^ l 2 4 - A P R - 1 9 9 3 
H u m a n c - t r n s p r o t o - o n c o y e n e f o r C S F - 1 r e c e o t o r . 
X 1 4 7 2 0 
c - f m s p r o t o - o n c o g e n e ; C S r - 1 r e c e p t o r , g l y c o p r o t e i n ; 
g r o w t h f a c t o r r e c e p t o r ; p r o t o - o n c o g e n e ; 
t r a n s m e m b r a n e c, I y c O D r o t e i n ; t y r o s i n e k i n a s e . . . . 
I n i t l : 54 I n i t n : 1 2 5 O p t 
8 5 . 0 ' - ; i d e n t i t y i n " 20 b p o v e r l a p 
59 
Figure 3 .36 . I l l , 
70 
L O O J S 
D E F I N I T I O N 
H U M C 0 4 1 3 1 3 3 D D O N A 
H u m a n r e c o g n i t i o n / s u r f a c e a n t i g e n 
PR I 
v C 0 4 ) * e n e , 5 ' 
0 1 ~ N 0 V - 1 9 9 4 
e n d . 
A C C E S S I O N 
KEYWORDS 
M 8 6 5 2 5 
g l y c o o r o t e i n . " i m m u n o g l o b u l i n s u o e r 
r e c o g n i t i o n a n t i g e n ; s u r f a c e a n t i g 
g e n e f a m i l y ; 
en „ 
S O U R C E Homo s a p i e n s D N A . ° . 
S C O R E S I n i t l : 3 4 0 I n i t n : 4 9 1 O p t 
75o3S* i d e n t i t y i n 7 b p o v e r l a p 
: 5 3 2 
Figure 3 .36 . IV, 
g b _ p r : h u m g p p S a 2 1 
LOCUS 
0 £ F I N I T I O N 
A C C E S S I O N 
K E Y W O R D S 
SEGMENT 
S C O R E S 
H.UMGPP 3 A 2 1 <6fl29 b p DNA PR I 2 6 = M A Y - 1 9 9 5 
H u m a n p l a t e l e t g l y c o p r o t e i n I l i a , e x o n 1 5 = 
M 3 2 6 8 6 J 0 5 4 2 7 
A l u r e p e a t ; i n t e y r i n ; p l a t e l e t f i b r i n o g e n r e c e p t o r ; 
p l a t e l e t g l y c o p r o t e i n . 
2 1 o f 2 1 . . . 
I n i t l : 3 1 0 I n i t n : <9 4 O p t : 
71.SH i d e n t i t y i n 2 5 5 bp o v e r l a p 
4 8 5 
Figure 3 .36.V, 
S b _ p r : h u m 2 4 d c 9 v z 
L O C U S 
D E F I N I T I O N 
ACCESS I O N 
KE <WU3US 
S O U R C E 
S C O R E S 
W'JH24r>C99Z 3 6 7 S bp O N A p?.i 0 6 - J U L ~ 1 9 9 5 
h o m o s a p i e n s ( s u b c l o n e 9 _ a 8 f r o * P I H 2 4 ) D N A s e q u e n c e . 
L 4 3 4 1 0 
I n t e r l e u i f i n g r o w t h h o r m o n e c l u s t e r o n c h r o m o s o m e 5 ( 5 q 3 1 ) . 
Homo s a p i e n s ( t i s s u e l i o r a r y : S u b c l o n e s i n o j T 2 f r o m P i c l o n e H 2 4 
U N A . . . . 
I n i t l : 3 3 8 I n i t n : 4 9 8 O u t : 
66,9% i d e n t i t y i n 4 0 2 bp o v e r l a p 
5 7 0 
Figure 3 .36 .VI , 
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g b _ o r : h u m b t x i i i 
L O C J S 
D E F I N I T I O N 
ACCESS K M ; 
K.E r JORDS 
SOURCE 
O R G A N I S M 
H U M 3 F X I I I 3 3 2 0 o 
H u m a n f a c t o r X I I I 
M 6 4 5 S 4 J 0 5 29( , 
b l o o d c o a g u l a t i o n 
H u m a n D N A . 
Homo s a p i e n s . ° « 
00 UNA 
v s u o u n i t 
P^ I 
c o m p l e t e c o s 
3 1 = 0 C T ~ 1 9 9 < . 
f a c t o r ; f a c t o r X I I I ; f a c t o r X l l l b l z y m o g e n . 
SCORES I n i t l : 7 6 I n i t n : 1 1 4 O p t : 8 6 
5 5 . 9 % i d e n t i t y i n 14 5 D P o v e r l a p 
Figure 3 .36 .VII , 
g b _ p r : h u m r e t o l a s 
LOCUS HUMRETBLAS 1 8 0 3 8 8 b p UNA PR I 2 3 - N 0 V - 1 9 9 4 
D E F I N I T I O N H u m a n r e t i n o b l a s t o m a s u s c e p t i b i l i t y g e n e e x o n s l - 2 7 / > c o m p l e t e c d s 
ACCESS I O N L I 1 9 1 0 
KEYWORDS n u c l e a r p r o t e i n ; r e c e s s i v e o n c o g e n e . " r e t i n o b l a s t o m a g e n e ; . 
r e t i n o b l a s t o m a p r o t e i n ; r e t i n o b l a s t o m a s u s c e p t i b i l i t y ? 
t u m o r s u p r e s s o r g e n e . . . . 
SCORES I n i t l : 7 6 I n i t n : 1 6 1 O p t 
5 2 . 6 ! ; i d e n t i t y i n U l b p o v e r l a p 
1 1 7 
Figure 3 . 3 6 . V I I I , 
! g b _ p r : h s t c r b v 
LOCUS HSTCRBV 7 7 7 4 3 b p ONA P R 1 2 0 - A P R - 1 9 9 4 
D E F I N I T I O N H u m a n V b e t a T - c e U r e c e p t o r ( T C R B V ) g e n e l o c u s . 
A C C E S S I O N U 0 3 1 1 5 
KEYWORDS 
SOURCE h u m a n . 
O R G A N I S H Homo s a p i e n s . . . 
SCORES I n i t l : 7 1 I n i t n : 2 0 6 O p t : 1 4 4 
5 7 . 3 * i d e n t i t y i n 2 3 9 b p o v e r l a p 
Figure 3 .36 . IX, 
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LOCUS 
u E F I h l l T I O N 




HUMHHCC6A 3 4 5 3 o p R I R N A P R I 0 7 ~ J A N = 1 9 9 5 
H u m a n MHC c l a s s I I I c o m p l e m e n t c o m p o n e n t C6 mRNA/ c o m p l e t e c a s . 
J 0 5 0 2 4 
c l a s s I I I g e n e ; c o m p l e m e n t c o m p o n e n t C 2 ; c o m p l e m e n t c o m p o n e n t C 6 ; 
c o m p l e m e n t s y s t e m p r o t e i n ? m a j o r h i s t o c o m p a t i b i l i t y c o n o l e i . 
H u m a n l i v e r , cDNA t o m R N A , c l o n e s l a m b o a - C 6 / C 5 G - 1 « : H I , 2 1 : 2 1 1 J _ . 
I n i t l : 6 2 I n i t n : 1 3 ^ O p t : 
6 3 . 9 ! ; i d e n t i t y i n 6 1 b p o v e r l a p 
6 1 
Figure 3.36.X, 
g b _ p r : h u m a f p 
L O C U S HUMAFP 2 7 5 5 3 bp UNA P R I 
D E F I N I T I O N H u m a n a l p h a - f e t o p r o t e i n g e n e , c o m p l e t e c d s . 
A C C E S S I O N H 1 6 1 1 0 
KEYWORDS a l p h a - f e t o p r o t e i n . 
SOURCE h u m a n . 
O R G A N I S M Homo s a p i e n s . . . 
2 6 - K A Y - 1 9 9 5 
SCORES I n i t l : 1 0 1 I n i t n : 1 3 8 O p t 
5 5 . 5 ? : i d e n t i t y i n 4 8 3 D P o v e r l a p 
1 8 4 
Figure 3 .36 .XI , 
j o _ o r : n s a t 3 
L O C U S 
D E r I IN I T I ON 
A C C E S S I O N 
KE YWORJS 
HS AT 2 1 4 2 0 6 bp U N ' « 
H . s a p i e n s g e n e f o r a n t i t n r o m j i n I I I . 
X 6 6 7 9 3 S 5 2 2 3 6 5 5 2 2 4 0 
a n t i t n r o a b i n ; a n t i t h r o m b i n 1 1 1 g e n e ; 
s e r i n e o r o t e i n a s e i n n i b i t o r ; s e r p i n . 
P R I 
A T 3 g e n e ; 
0 3 - N 0 V - 1 9 9 4 
p l a s m a p r o t e i n 
SOURCE n u m a n . o . . 
SCORES l n i t l : 5 3 I n i t n : 1 2 5 O o t : 
5 5 . 8 ^ ; i d e n t i t y i n 1 6 3 b p o v e r l a p 
6S 
Figure 3 .36 .XII , 
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g b _ p r : h s c u z n s o 
LOCUS H S C U Z N 5 0 4 0 0 3 b p D M PR I 
D E F I N I T I O N H - s a p i e n 3 g e n e f o r C u / Z n - s u p e r o x i d e o i s n u t a s e , 
A C C E S S I O N 2?V32>6 
KEYWORDS C u / 2 n - s u p e r o K i ae d i s m u t a s e . 
SOURCE l i u m a r , . 
O R G A N I S M n o m o s a p i e n s . . . 
1 2 - A U G - 1 9 9 4 
SOUPES I n i t l : 3 5 2 I n i t n : 5 4 5 O p t : 5 l « 
7 5 . 9 ' A i d e n t i t y i r . 2 3 2 b p o v e r l a p 
Figure 3 . 3 6 . X I I I , 
g b _ p r : h u m f m r l s 
LOCUS H U r . F M R l S 1 5 2 3 5 1 D D DNA P R I 1 R - J A N - 1 9 9 5 
I J E F M I T I O . N Homo s a D i e n s f r a g i l e X m e n t a l r e t a r d a t i o n p r o t e i n (F MR = 1 ) g e n e ( o 
a l t e r n a t i v e s o l i c e s ) , c o . n p l e t e c o s . 
A C C E S S I O N L 2 9 0 7 4 L 3 3 5 0 1 
KEYWORDS f r a g i l e X m e n t a l r e t a r d a t i o n s y n o r o i t p r o t e i n ; 
f r a g i l e X s v n d r o m e , ' r e p e a t r e g i o n . . . . 
S O U S E S l n i t l : 69 I m t n : 1 0 6 C p t : 7 1 
5 5 . I X i d e n t i t y i n 114 bp o v e r l a p 
Figure 3 . 3 6 . X I V , 
446 G s u I 
441 Fokl 
239 BspM I 438 BstX I 
179 Bsg I 400 Ear I 
157 B s r l 364 Tfi I 
151 B b s l 290 S(aNI 426 Hael 
139 BspH I 285 BsaB I 420 Hinc II 
95 Drd I 235 Bsm I 364 Hint I 
91 Xba I 207 Ssp I 351 Alwl 
647 BsiY I 
639 Mme I 
553 Mspl 
553 Hpall 
525 Sau96 l 
525 Ava II 






841 Nla IV 988 BsmA I 
808 Mae III 987 Bsa I 
_ L _ L J_JL 
] 
NTG S 13 RV+UP 1014 b a s e pairs Unique Si tes 
Figure 3.37.1, Restriction map of N T G + I 3 . 
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I 10 I 20 I 30 | 40 
1 GATCATGCAA TAGTAAGAAG TTCTAAACTA TACATATTCC 
81 CCCAAATCTA TCTAGACAGA GTTGTCATCA CAGAGTATTG 
161 TATATCGTTC TTTATTGGCT GCACAATCAC AATTGGGCTG 
241 AGGTTGTTTC CACTTTGTAC AACGGAATTA TCAGATAACA 
321 TCAATCAATT TACTTGGTAT AAAATCCCAA GGATCAGGGA 
401 AAGAGATTAC CACCAGCTAG TTGACAGGCC AAACATTCCA 
481 AAGACAGGCT TACTGAAAAT TTTACTTCCA T T T A * * * * * G 
561 GAATACCATT TGTGAGGCGA CAACAGGTAG AGAAGGGAAG 
641 CAACTGCCTT GGAGGGGGAA GTAAATCCCC AAAGATAAAC 
721 GTTGATTTTC CCTGAAAGTG AAGTTTAACT CAGTTTTTCG 
801 TCGTTCTGTC ACCCAGCCTG AAGTACAGTG GTACAAAGTT 
881 TGTGCCTCAG CCTCCCGAGT AGCTGGGATT ACAGGCGTGC 
961 TGGGGTATCA CCATGTTGTC CAGGTTGGTC TCGAACTGCT 
I 10 I 20 I 30 I 40 
| 50 | 60 | 70 
CACGCACCAA AATGTTTCCT TTTTCATTTG 
AATAGTGTAT AATTTGCTTC ATGAACATCT 
GTGGATAATA TTTACTGACA TACTTATTTT 
CCACGATCAG CATCTTAGTA TGCAGACTTC 
CTTGAATCTG AC ATTGTTCA TAATGCTTGC 
CATCCCTGGA GATGTATTTT GCCCAAACTT 
ATTTGGACCA GGATAATATG CTGCATTGAA 
CAATTGTAGA AGAAGGTTGT CAAGAAGGCC 
TTTGGTGAAG GTGAAATAAT TTAGCAGATT 
TTCTCTCTGG TATATTATCA TAGTATTATT 
GGCTCCCTGC AACTTCTTCC TCTGGGGTTC 
ACCACCACGC CTGACTTAAT TTTGTATTCT 
GCCCTCAACT GATC 
















Figure 3.37.11, D N A sequence o f NTG+13 . 
NTG+33 
S a c I EcoRI 
S a u 3 A SauSA 
RV , 
Sequenced 
Figure 3.38, NTG+33 sequenced regions. 
145 Alu I 
144 Hind III 
112 Eco57 l 
101 Pisa I 
101 Csp6 l 
97 Ddel 179 
_|_ 
226 Tth111 I 
198 NspCI 
198 Nsp7524 I 
198 NspI 
Xmnl 
377 SfaN I 
366 Hph I 
333 S s p I 414 
440 Mae II 
473 TaqI 
436 Hinc II 
Mae III 
J L 
Untitled Sequence # 24 502 b a s e pairs Unique S i tes 
Figure 3.39.1, Restriction map of NTG+33. 
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I 1 0 I 2 0 I 3 0 | 4 0 | 5 0 
1 C G G T A A G A T A T T T T T A A A A A A T T C T T A C C C T A T G T T T A A T G T T T T C A A A A 
8 1 C A G T G G C A A A T A C A T T C T C A G T A C C A C T A C A C T G A A G T A G A A T T C T G A A T 
1 6 1 A T T A G T C A A T A T G T A A T A G A A G T A T T T C A A G G T T A T A A C A T G C A A T G C T A 
2 4 1 G A T A A A A C T T T T G T T T C T T A A A G A C T A G A C T G T T T A A T C T T A T T T T T C T A 
3 2 1 T A A C A T G G T A A T A A T A T T A T T A A A A T C C C A C C T T T C A A A A A G T G A G G T G A 
4 0 1 T G G G T C C C A G T T T G T G A C T G C C T A A A A G A A A A C C C G T T G A C G T T T A G A A T 
4 8 1 C A A A T T A T T T C C C T T G T G T T T A 
| 1 0 | 2 0 | 3 0 | 4 0 | 5 0 
| 6 0 | 7 0 | 8 0 
T T C A A T A G A A A A A A A T A T A A G G T C C T T A T A 8 0 
T C C T A T T T T T T C A A A G C T T T T T T T G T T T A A 1 6 0 
G T T T A T A T A T T G A T T G A C A T T G T C T A A T A A 2 4 0 
C T G G A T A A A T T A T T T C A G A A T T T C T A A T T A 3 2 0 
T A A T T C G C A T C T T T T G T C T T T C A A T T G T G C 4 0 0 
A A C T T T T T A A A A A C T C C C T C T C T C G A A G T T 4 8 0 
5 0 2 
| 6 0 I 7 0 | 8 0 J 
Figure 3.39.11, D N A sequence of N T G + 3 3 . 
3-2- Protein analysis 
© Standard curve results: 
Protein cone for std. (Lig) O D 5 9 5 OD595 duplicate Mean 
0 0 0 0 
5 0.153 0.159 0.156 
10 0.307 0.295 0.301 
17.5 0.448 0.480 0.464 
25 0.602 0.594 0.598 
35 0.751 0.757 0.574 
45 0.940 0.934 0.937 
55 1.17 1.20 1.185 
Table 3.3. 
© From each cell line, [SK-N-SH] and [SK-N-Be2c], 10(il of nuclear extract was added to 
2.5ml of diluted dye and read O D 5 9 5 (see chapter 2, protein analysis). 
® The value of protein (Lig) was read from the standard curve and calculated the value of JI 
g protein / ml. 
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Cell line OD 5 9 5 Protein p.g / pi 
SK-N-SH 0.19 0.9 
SK-N-Be2c 0.40 1.6 
Table 3.4. 
• Protein extracts from SK-N-SH and SK-N-Be2c were separated by SDS-PAGE, to 
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Figure 3.40, SDS P A G E of protein extracts from S K - N - S H and SK-N-Be2c. 
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3.3. Colony Hybridization 
To ascertain whether any of the clones isolated had previously been identified as NTG 
clones from SK-N-Be2c, the clone NTG-21 from that cell line was used as a probe 
against colony blots of the NTG library from SK-N-SH cells. As shown in figure 3.41 it 
would appear that no significant hybridization to NTG-21 was shown by any of the SK-






Figure 3.41, Colony blots probed with NTG-21 (see method 2.2.2.10 & 2.2.2.11) 
78 
4. Discussion 
The project was carried out in order to identify potential target genes for N-myc using the 
cell line SK-N-SH. 
The method used to generate genomic library has led to approximately 400 clones being 
isolated, some sequenced, and sent to be compared with known DNA sequenced using 
"Daresbury" data bases. This procedure can potentially identify genes present in the NTG 
library. 
Out of the 400 clones, 114 NTGs had their insert size calculated, four partially sequenced, 
one had a low affinity N-Myc binding site "CAT GTG", plus C-Myc binding sites CAC 
GTG, and TCT CTTA (see table 3.2. page 44). However the final resolution of which 
clones are true in vivo targets for regulation by N-myc wil l await the cloning these putative 
regulatory sequences into reporter plasmids and monitoring activity in N-myc expressing 
neuroblastoma cells. 
Colony hybridization was done for the 400 clones to check i f any had the NTG-21 insert 
which was isolated previously in the same lab from the cell line SK-N-Be2c. The result 
was negative. 
The study of the outcome of the homology search was based on high similarity over 
potential extended length, compared with the actual length of the sequenced part, and i f 
the homologue is of interest by looking at the known neuroblastoma literature ( i f the gene 
plays a role in Neuroblastoma cells) 
From the obtained sequence, the comparison data and considering the role of every gene; a 
substantial amount of information was gathered, some, in a way or another, play a role in 
neuroblastoma cells and a lot of homology had no role at all, and most were intron genes. 
Some of the genes picked out by sequence comparison include: 
• Human pre-B cell, cDNA to mRNA. Human recombination activating protein (RAG-1) 
gene [66.0% identity in 203bp overlap to NTG+8]. 
- B-cell, also called B lymphocytes give rise to plasma cells, which produce antibodies. 
This defence system by B-cells is called antibody-mediated immunity or humoral 
immunity because these antibodies present in the blood stream. 
During development, antibody genes are re-arranged and 'N-myc expression is switched 
off, and some studies have revealed that down-regulation of N-myc expression in the later 
stages of B-cell development is mediated primarily at the level of transcriptional initiation 
and that dominant, trans-acting factors present in more mature B-lineage cell lines act to 
down-regulate the transcription of N-myc. 
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• Human DNA sequence from cosmid HW2, Huntington's disease region [62.5% 
identity in 120 overlap to NTG+5]. 
- Huntington's disease formerly Huntington's chorea, is a hereditary disease of the central 
nervous system caused by a mutated gene on chromosome 4. (Neuroblastoma tumour arise 
from neural crest cells which form part of the sympathetic nervous system). 
• Human retinoblastoma susceptibility gene [52.6% identity in 441 overlap to NTG+8]. 
- Retinoblastoma is a hereditary malignant tumour of the retina (delicate, multilayered, 
light-sensitive membrane lining the inner eyeball and connected by the optic nerve to the 
brain), transmitted as a dominant trait and occurring chiefly among infants. 
Subsequent studies revealed amplification of N-myc in retinoblastoma and indirect 
evidence has indicated that the product of the retinoblastoma gene (pRb) may be necessary 
for the beta type transforming growth factor (TGF-beta) suppression of N-wyc expression 
and not for TGF-betal inhibition of branching morphogenesis. Therefore suppression of 
N-myc is not necessary for inhibition of branching morphogenesis by TGF-betal, (TGF-
betas are potent inhibitors of epithelial cell proliferation). [Hannon G, Demntrick G, Beach 
D; Isolation of the Rb-related pi30 through its interaction with CDK2 and cyclins: Genes 
Dev. 1993, 7 (12A), 2378-2391] & [Friend S. H, Bernards R , et al. ; A human DNA 
segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma: 
Nature 1986, 323 (6089), 643-646.]. 
• Human vascular cell adhesion molecule-1 (VCAM1) gene [61.5% identity in 117 
overlap to NTG+8], [70.5% identity in 661 overlap to NTG+5]. 
- Vascular cell adhesion molecule-1 was first identified as a protein that appears on the 
surface of endothelial cells after exposure to inflammatory cytokines. 
Through interaction with it's integrin counter receptor VLA-4, VCAM-1 mediates cell-cell 
interactions important for immune function. The recruitment of immune cells to the 
endothelium is a complex process involving the interaction of ligands or counter receptors 
on the surface of endothelial cells with receptors on immune cells, and in addition to 
endothelial cells, VCAM-1 is also expressed on lymphoid dendritic cells, and stromal 
fibroblasts in bone marrow, and on some tissue macrophages. 
Endothelial cell surface ligands may be involved in metastasis of tumour cells, as it has 
been proposed that the interaction of tumour cells with activated endotheliun is a 
mechanism that facilitates the migration of circulating tumour cells into tissues. Also small 
cell lung cancers (where N-wyc is amplified) express LFA-1 and MAC-1 integrin which 
binds to ICAM-1 (a member of the endothelial cell ligands). [Iademarco M . F, McQuillan 
J. J, et al.; Characterization of the promoter for vasculear cell adhesion molecule-1 
(VCAM-1): J. Biol. Chem. 1992, 267 (23), 16323-16329] 
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o Human p53 gene - associated protein p53, cellular tumour antigen p53 [66.0% identity 
in 203 overlap to NTG+8]. 
- It was thought in several reports on p53 that this genotype is found to have virtually 
exclusive wild-type status in primary neuroblastoma, and that p53 plays no role in the 
development of neuroblastoma, but recently it was reported that the vast majority of 
undifferentiated neuroblastoma's exhibit abnormal cytoplasmic sequestration of wild-type 
p53. This inability of p53 to translocate to the nucleus presumably prevents the protein 
from functioning as a suppressor. 
The loss of p53 function in neuroblastoma seems to play a major role in the tumorigenesis 
of undifferentiated neuroblastoma (neuroblastoma might abrogate the transactivating 
function of p53 inhibiting it's access to the nucleus, rather than by gene mutation). 
[Zauberman A, Barak Y, et al.; Sequence-specific DNA binding by p53: identification of 
target sites and lack of binding to p53-MDM2 complexes: EMBO 1993, vol. 12 no. 7 pp. 
2799-2808]. 
o H . sapiens genes TAP1, TAP2, DOB, DOB gene, LMP2 gene, LMP7 gene, Major 
histocompatibility complex class I I [79.3% identity in 29 overlap to NTG+8]. 
- Some studies are being carried out to determine whether a antitumour immune response 
would be generated by introducing Xenogeneic class I I MHC genes into tumour cells, thus 
some approaches have been made to use retroviral-mediated transduction of class to MHC 
genes into human tumour cells for an effective alternative to current cancer treatment. 
[Glynne R, Kerr L. A, et al.; The major histocompatibility complex-encoded proteasome 
component LMP7, alternative first exons and post-translational processing: Euro. J. 
Immunol 1993, 23 (4), 860-866] 
• H . sapiens genes TAP1, TAP2, DOB, DOB gene, LMP2 gene, LMP7 gene. 
- The LMP7 gene maps to human MHC class I I region within 15Kb of LMP2 and 
between TAP1 and TAP2. 
TAP1 and TAP2 have homology to the ATP binding cassette (ABC) superfamily of 
transporters and have been shown to play a role in the processing and presentation of 
endogenous antigens through MHC class 1 (neuroblastoma has a decreased expression of 
the MHC class 1 antigen which correlates with high level of expression of the N-myc gene, 
thus expression of MHC class 1 antigens may result in neuroblastoma cells being more 
resistant to T-cell mediated immune surveillance). [Beck S, Kelly A, et al.; DNA 
Sequence analysis of 66kb of the human MHC Class I I region encoding a cluster of genes 
for antigen processing: J. Mol. Biol. (1992) 228, 433-441]. 
• H . sapiens mRNA for Rb2/pl30 protein [55.7% identity in 219 overlap to NTG+5]. 
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« Rbr-2 = retinoblastoma susceptibility gene. 
- Rb2/pl30 is a member of the Rb family (Retinoblastoma). 
pRb and Rb2/pl30 share considerable homology in their pocket domains, they share two 
additional regions of significant identity near their amino termini, they not only share 
primary sequence homology but also functional similarity, each of these proteins combine 
specifically to the viral oncoproteins, SV40 antigen and adenvirous EIA. 
The structural and functional similarities between Rb and Rb2/pl30 gives two possibilities 
for the role of Rb2/pl30 either it may act as a inhibitor of cellular proliferation or as a 
tumour suppressor gene (Rb is the retinoblastoma susceptibility tumour suppressor gene, 
pRb is the product of this gene which has been shown to play a key role in the regulation 
of cell division. [Mayol X, Grana X, et al.; Cloning of a new member of the 
retinoblastoma gene family (pRb2) which binds to the EIA transforming domain: 
Oncogene (1993) 8, 2561-2566]. 
Other genes picked out by sequence comparison include: 
• Human gene for dihydrolipoamide succiny 1 transferase. 
• Human thymidine Kinase gene. 
• Human recognition surface antigen (CD4) gene glycoprotein, immunoglobulin super 
gene family. [Edwards M . C, Gibbs R. A; Human dinorphism resulting from loss of an 
Alu: Genomics 1992, 14 (3), 590-597] 
• H . Sapiens 3'flanking region for estrogene receptor gene. [Keaveney M , Parker M . G, 
et al.; Identification of a functional role of the 3' region of the human oestrogene 
receptor gene: J. Mol. Endocrinol 1993, 10 (2) 143-152] 
• Human c-fms proto-oncogene for csf-1 receptor. 
• Human alpha-fetoprotein gene. [Stocker N . G, Cheah K. S, et al.; A highly 
polymorphic region 3' to the human type I I collagen gene: Nucleic Acids Res 1985, 13 
(13) 4613-4622] 
• Human mRNA for second protein of Inter-alpha-trypsin inhibitor complex. 
• Human ATP synthase beta subunit (ATPSB) gene. 
• Human acetylated low density lipoprotein (ACLDL). 
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Homo Sapiens p-selection CD62 (GRMP) gene, 5' end and promoter region. [Pan J, 
McEver R. P; Characterization of the promoter for the human P-selectin gene: J. Biol. 
Chem. (1993) 268 (30), 22600-22608]. 
Human antigen CD36 (Alu repeat). 
Human breakpoint cluster region (BCR) gene. [Gu Y, Alder H, et al.; Sequence 
analysis of the breakpoint cluster region in the ALL-1 gene involved in acute leukemia: 
Cancer Res. (1994) 54, 2327-2330]. 
Human fragile X mental retardation gene. [Nicola N . A, Metcalf D; Subunit 
promiscuity among hemopoietic growth factor receptors: Cell (1991) 67 (1) 1-4]. 
Human insulin receptor gene. [Elbein S. C; Molecular and clinical characterization of 
an insertional polymorphism of the insulin-receptor gene: Diabetes (1989) 38 (6), 737-
743]. 
Human T-cell receptor beta-chain. [Slightom J. L, Siemieniak D. R, et al.; Nucletide 
sequence analysis of 77.7Kb of the human V beta T-cell receptor gene locus, direct 
primer-walking using cosmid template DNAs: Genomics (1994) 20, 149-168]. 
Human vitamin D binding protein gene. 
Human interferon-beta-2 gene. 
Human interleukin-6 receptor (ILb) gene. [Bowcock A. M , Kidd J. R, et al.; The 
human 'interferon-beta 2/hepatocyte stimulating factor/ interleukin-6' gene, DNA 
polymorphism studies and localization to chromosome 7p21: Genomics (1988) 3 (1) 8-
16]. 
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However the most intriguing and exciting of these potential N-myc targets was 
found by my lab. Colleague Dr. D. Pearson in clone NTG-21 using her cell line SK-N-
Be2c (same procedure was used). 
NTG-21 contains a sequence conserved with one found in intron one of the human DOPA 
decarboxylase gene. The degree of sequence identity suggests that they are not one and the 
same, but represent similar genes.m DOPA decarboxylase is involved in the diosynthesis 
of dopamine, epinephrine, norepinephrine and serotonine neuronal tissue, it shows high 
activity in both neuroblastoma and small cell lung carcinomas, another tissue with N-myc 
amplification. As N-myc and catecholamine levels both decline after retinoic acid 
induction, it was speculated that NTG-21 is part of a gene closely related to DOPA 
decarboxylase possible encoding an isoenzyme, further analysis of NTG-21 is bing carried 
out by Dr. Pearson to isolate the gene, obtain it's true identity, and find out whither or not 
it is under the control of N-myc. 
Other research work is being carried out at Newcastle University to try to identify genes 
that are coamplified with N-myc, and determine how they affect prognosis by looking for 
genes which map close to N-myc such as DEAD box (DDXI) which may have some role 
in prognosis and response, ornithine decarboxylase (ODC), ribonucleotide reductase 
(RDR). 
4.1. Conclusion: 
Although no final conclusion was obtained with respect to the effect of N-myc upon other 
genes in neuroblastoma cells, the result of my findings would play a conducive part 
towards future work in that field, as more time is needed and more work needs to be 
carried out on the rest of the 400 clones, for example completing the sequencing, computer 
analysis to identify sequence homologies and binding sites. Once any gene of interest has 
been identified a Northern blot will be done to determine whether or not it is under control 
of N-myc, using three different cells as the levels of gene expression may depend on the 
concentration of N-Myc relative to other b-HLH-Z proteins: 
=> SK-N-Be2c Neuroblastoma cell with amplified N-myc. 
=> SK-N-SH Neuroblastoma cell with a single copy of N-myc. 
=> Normal cell. 
Experiments would be performed under normal culture conditions and after cells have 
been induced to differentiate with retinoic acid, as it has been shown to be one of the most 
potent chemical inducers of differentiation in human neuroblastoma. Until then the 
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5 8 2 0 5 8 3 0 5 8 ^ - 0 5 8 5 6 5 8 £ C 5 B 7 0 
110 Z l d 2 2 0 2 5 6 2*,<3) 
5u < 3 - n S 6 C T C A T C C C T A r A \ r c c C A G C A C T TTGCGAGGC T G G A G T B G G I T A * TTuC r TG^GCC 
I • I I I • I * t i l l I . • < I . I I I • I > I . I • I i l l I t I I t l t 
I I I I I I I I I I I I I I I < t I I I I i I • I • I I 1 I I I I I I I I I I I I l i l t 
hummna G I 6 G C T C A C < S C C T G G A T T T C C A G C A C T T T G G G A G G C T G A A 6 C A G . G T G G A T C A C C T G A G T T 
5 8 8 0 S83o 5 ? 0 0 5910 5<?l0 5 < ? 3 © 
Z S G 2 * 0 2 7 0 28o 290 3oo 
5M T A A C A T C A G A C G M 3 C C T 6 G T C A A C A T A C C A A A ACC CC \ T C T T T A C A A 4 A ^ A i \ r A C T A 
• * • • < ! • i I . I . t t . I l t I * | . I . I . I t I . I , . I ( t i l l I • 
• ( * * > * l l l l l l l l * I I I I I I I I I I « • I I • I I I f l l l l l I I 
h *J wn ;i a T C G G A G T T C G A A A C C A G C C T G G C C A AC A T G G T G A A S \ C C C C A T C T C T A C TAA A a A T A \ T A A 
5<?4<J 505O J fc tO 597 6 5986 5 9 9 0 
IL0 32© 350 34© 3£e 36© 
S U . A A A T T A G C X A f i C C A T X i C T G G C A C A T C C C C A r A G T C C C A A A r A C 1 C AG6A6GCT6AG6CC-G 
• • • ' • * * • ' I * I t i i | . . I . I . I I . I . I • I * I • I . I * * t * 
l « l l l l l l I I I I l l l l 1 1 1 ! I | l l l « * l » t t I t t t t t t l l t t t t t 
i i u m n f » i A A G T T A G C C G G G C G T G A T G U C G O G T GC C T G T A A I C C C A A C T A C I r G \ j G A G G C T G A G I C A G 
<Sooo Ge>]& 6G2® 6OSO 6040 6QSQ 
3 7 0 3 8 6 190 4 0 0 4 1 6 4 2 0 
5u 0 A G G A T T G C 7 T C A G C C r GGAAGGTG A AGGmSCAGTGftGG- - C A A T C A C A C C A C T 6 C A C T 
• t * • » . » . « • • 1 • • 1 ! • ! I • I t t . I . I t • . • . t . I 
i l l 1 * * I 1 I » • t 1 1 • I I I 1 • • 1 • I t * • 1 • 1 1 1 i l l 
ku.unnd G A G A A T C G C T T - G A A T C C G G 6 A A G ' T G G A G G T T G C A G T C A G C T G A G A T C A G 6 ~ C C A £ T G C A C T 
606O 607Q 6080 6090 6L6O 6L16 
A3<3> 4<W> 4 5 0 U6& (,76 4 g 6 
5u C C A G C C T G A C T G A C - A C A A T A A G A C C T C G T C T C <S A AAAA AA A T FA T T G 6 A A G T F F T A T A r 
« t t • t I I > t I . i l l t 1 1 1 t i l l I 1 I • I 1 I • i t 
l l l l l l l * I I I I I I I I * I I I I ! 1 1 1 1 1 1 * 1 I I 
Wu,nnna CCA6CC rGGGCAACA A G A G T G A A A T T C C A T C f C C A A A A A A A A " . A A T A A 1 AC A A T A A T A A 1 
6l20 6 i 3 0 6LAO 6150 6L60 6 1 7 0 
4 9 0 5 U 0 5 1 0 5 2 0 5 3 0 5 4 0 
T A T T C I T C C C f C T A G I r o G A C r T i . C A T T C C A C T C C A C r C G G C C A G C A G A A C ( T A T C C T A T 
liu.n.nna A A T A A T A I r I TfcGAC, G F T C A R C A A G T T G I A u T A F G G G T C A G A A T 1 T C A T T C C T T T T A A G 
6 l g O 6190 6 2 0 O 6 2 1 0 6 2 2 0 6 2 3 0 
NTG+5 
88 
L O C U S HSR82P130 3249 bp ftNA MM 1 4 - 1 ^ - 1 9 9 * 
• D E F I N I T I O N H . s a p i e n s mQUA f o r P p 2 / p l 3 C p r o t e i n . 
A C C E S S I O N X745C4 
MID g397147 
KEYWORDS E \ A o i n d i n g p r o t e i n ; r e t i n o n i a s t o m a - a s s o c i a t e d p r o t e i n , 
SOURCE h u m n . „ . . 
S C U R E S I n i t L : 6i [ n i t n : t i l Opt : 112 
$5.7'-. i d e n t i t y i n 2J.9 bp o v e r l d o 
57V 569 5 5 9 549 
c3 6A \ G A A G T A A A A C f 'SuAGGGAAArA A T C T A T A A I T I c T T A C r 
I • I I I . I • I t I . . I • I • t « 
• I • I I I t I 
hs rh2p A G C T A C C G C A C C A T G A G C G A A A G C T A C A C G C TG6A G C G A A A i G A K T T C A T J 
40 50 60 70 go 
53'? 5 l ? Sfl? 4<?<? 4 « 9 
5 s c 3 GGOAAAAATGGSACT&r| r i T C A f G T A T T C ^ I G G G T A A G T A T T A T I T A C G * A T & G 6 A T T & 
; 1 • : i • * • » • » . i . i . t t . i « • i i * . • i 
• * ' I I * I f | | I I I ! I l l l | l l l l l t l I I 
hs rbZp G G T T A G C A T G T6CCT T A T A T G T - G G C T I G C A 6 A A - - A A T C T & T T C C A A C T & T A A G C 
90 l&O 110 120 136 
479 4 f 9 4,S9 4 4 ? 43? 430 
5 s c 3 * A A 6 A S A A C A 6 G A T T C C G C A T C * A f T T r A T T T T T A A G A G A A T - T T S C T A T G G G C A G A — A 
! I ! ; ; i l l ! ' * < * * * * * i i i , i , * . i t I . I i i i t i 
* 1 • • * i • i i i i i i i i t l i t • i t i * i i i • • • i i i i i 
ns rb2p A A A G - G & A C A G I G G A A G G A A A C T A T G T A T C T T T A ^ C T . - I S A A T C C T G A A M G1TCAGAGCA 
1 4 0 1 5 6 1 6 0 170 1%Q 190 
419 i (J? 399 3o9 379 
5 s c 3 G T C C C T G A T — A A A T A T I G G T T G G T A T A G A C A A 6 T G G A T A 6 A A A T 6 G C A A 6 T " G T C T G G ~ T T 
I « 1 1 
ns rb2p C A G C T f * A T C G A A T T \ T r T A A T A A G A T G A A G A A & T G G G A A G A C A T G G C A A A T C 1 A C C C C C 
200 210 220 230 2 40 250 
349 3 5 9 349 33? 329 319 
3sc3 A T A T T I C A G 1 T A C T C G C T T A T C T G A A C T C T T r C A TATT A T A I G C C A A A A C A T G C A T A C . A G 
4 l • 
I I I I I I I l 
n s r b 2 p A C A r T 1 C A G A GAA C G TACTOA G A G A TTA G A AAGAA AC 1TCACToT TTCTGCTGTAATTTI 
2 <50 270 280 290 300 310 
L O C U S H U M C 0 3 6 A 2561 bp O N A I 03-MAR-1V95 
O E F I N I I I Q N Human a n t i g e n CD36 Qene* a l t e r n a t e exons 2a and 2b and exon 3. 
ACCf .oS lON L0<584? 
N i l ) Q<591762 
K^rWOROS A l u r e p e a t ; a n t i j e n C 0 3 6 . 
SOURCE Homo s a p i e n s ( t i s s u e l i b r a r y : EwclL 4," 0"A. . . . 
SCOPES I n i t l : 69 In i t n: 112 O p t : <$9 
9^.77J i d e n t i t y i n 19 bp o v e r l a p 
410 420 430 440 430 4o0 
5s c 3 C C A A C C A A T A T T T A T C A G G G A C T T C T G C C C A T A C C A A A T K T C r T A A A N A T A A A A T T G A T 
i • ' • 
I I I I I I I I I I I I I I I I I I 
h j m c J 3 AACATGACTCCATIGCTGTCT TAAATATAAA IACC A A A T TC T"A T T A A A A GC T GTCT A CAG 
2 O ? 0 2O80 2010 2100 2110 2 1 2 0 
^70 4€0 U96 S O d 510 5 20 
5s c3 < S C C G A A T C C T C T T C T C T I T C A A T C C C A 7 T C G T A A A T A A T A C T T A C C C A T G A A T A C A T G A A 
nu.nc J 3 &TATGCATGTTA6T* G A A A T A A T T G T T " T T A A G T " F A T G T C C A A A G A G C A T G T T G 6 C A T & C T 
2 l 5 C 2140 2150 ? l 6 0 2 1 7 0 2 l f l O 
NTG+5 
89 
g b _ p r : h u m r e t b l a s 
LOCUS HUMRETBLAS 180388 bp DNA P R I 23~NOV=1994 
O E F I N I I I O N Human r e t i n o b l a s t o m a s u s c e p t i b i l i t y gene eaons 1=27/ c o m p l e t e cch 
A C C E S S I O N L11910 
KEYWORDS n u c l e a r p r o t e i n ; r e c e s s i v e o n c o g e n e ! r e t i n o b l a s t o m a gene." 
r e t i n o b l a s t o m a p r o t e i n ; r e t i n o b l a s t o m a s u s c e p t i b i l i t y ; 
tumor s u p r e s s o r g e n e . = = „ 
SCORES I n i t l : 76 I n i t n : 161 O p t : 117 
52 .6 ' i i d e n t i t y i n 441 bp o v e r l a p 
J.U 20 30 40 50 
8 r GATCATTTTGAAAKTTTGACCTTTATAT TTTAATGAATAAAAT A T T ~ ~ = ~ - AGT 
i i a • i i i t i i i t i i i i * • 
humret TATGATTAGTAGTTTTAATTCAAAATA AAAATGGTATGTTGAATAAAATATTACATAAAC 
107790 107800 107810 107820 107830 107840 
60 70 80 90 100 
6r AGTTATTAGTATAAAATAATTTATGTCTTTT—•=GGACTTAGCAT—CCAGTATTTCTTT 
: : : : : ; : :: : : : : : : 
humret ATAAATTAGTATAAAATAATTTA-GTAAATTAAATCATTTAATATAAAAAGGAATTCAAA 
107850 107860 1 0 7 8 7 0 107880 107890 107900 
110 120 130 140 150 160 
rfr TTTAATAAAGA-—AAATAATTATTCTCTTGCAATATACTGTGTTTACCTGGGTTTTGA 
: : : : : : : : : : : : i : ; : : : : : i : 
numret GACATTACAGATTGGCACCACATAATTTAAGTCAGT-CACTTTTAGACACTAAATAACTT 
107910 107920 1 0 7 9 3 0 107940 107950 107960 
170 180 190 200 210 220 
dr AAA6TGATGTTTCCTAATATGAGAAAGCCATTTACATTTTTAAATCTACAAAGGCAAATG 
: : : : : : : : : : : : : : : : : : : : : : : : : : ; : : : : : 
numret TAAGAGATTTTTTTTA—ATGAAGGAACAAATCAAA ATGGCTCAGAAAAATCAGATG 
107970 107980 107990 108000 108010 
230 240 250 260 270 279 
3 r GAATGG-TAC-TAAATTATTTATATAATAATGTTTAGATGGTGGCCCTTATAACATTCTT 
: : : : : : : : : : : : : i : :; : s : : : : : : 
numret GAGTGGATACACAAATAAAATACATGT TAATGCTTA AC AC ATTGAATACAAATTT 
103020 108030 108040 108050 108060 108070 
2d0 290 300 310 320 330 339 
eir TCTATACTTCCTACAGAGTTGGGGATATGCAATCC TGGAATAT TTCTGGGAGCTAATCCT 
: : : :: : : : : : : : : : : : : : : : : : : : : : : : : : : 
humret TCTTTA—TACTAAAGACTTTAAAATGT-CCATGTGTTAATTTCTTTTGGAGGTGGAAAA 
108080 108090 108100 108110 108120 
340 350 360 370 380 390 
dr T TAGCTTGATGAATGAAACAAGACTTT T-AAATAAAATTAAACTTTCAAAT — TATCCAG 
* ! * ; .' ! ! » i • i » i » » * i t * * « • « i • • * • i 
• » i • • i • i t * i t i t i i t i i * i i i i i * t • I I I I 
numret A TAGTTTGTCCA AAAAGACACTXTTCACAGTTGAAGGAACTTGAAAGTTCTGTCCCA 
108130 108140 108150 108160 108170 108180 
400 410 420 430 440 450 
3r G TAATGGGC C T - G T C TTTTAATTCAAT GGATATGGAGCATAATGAAT TA TCCCCTGTTCA 
* * * t l t t J I I t I I | I I I • I I I S l l l l l l 
* * * ( I I I I I I I l « l i l l • I I I I I t I I I ! 
numret G TGA—GTCCTAATGGTTT TATTTCAGGCAGCAGATTCATTGTCAAATA TCTTACTTTTT 




108250 108260 108270 108280 108290 108300 
NTG+8 
90 
j b _ p r : h u m r e t b l a s 
LOCUS HUMR ETBLAS 180388 bp DNA PR I 23-NOV-1994 
O E F I N I T I O N Human r e t i n o b l a s t o m a s u s c e p t i b i l i t y gene exons 1~27 , c o m p l e t e c d s . 
A C C E S S I O N L11910 
KEYWORDS n u c l e a r p r o t e i n ; r e c e s s i v e oncogene? r e t i n o b l a s t o m a gene; 
r e t i n o b l a s t o m a - p r o t e i n ; r e t i n o b l a s t o m a s u s c e p t i b i l i t y ; 
tumor s u p r e s s o r g e n e . ° . . 
3CURES I n i t l : 118 I n i t n : 192 O p t : 174 
8 6 . 4 J ; i d e n t i t y i n 66 bp o v e r l a p 
380 390 400 410 420 4 50 
du A A T C T C G G C C U T C C C G G G T C A G G G T T C A T T A T A C A C C A G G G G A G T A C T A T G C A G C C A T A 
1 1 1 ( 1 * 1 1 1 ( f t i l l t « » * i * t » » » l t 
* I t I I I I I I I I I t l l l l l l l l l l l l l l 
numret T G A T A G A C T G G A T T A A G A A A A T G T G G C A C A T A T A C A C C A - T G G A A T A C T A T G C A G C C A T A 
168180 168190 168200 168210 168220 168230 
440 450 460 
i u A A A A T G G A T G A G T T C A T G G C C T T T A C T A G G G G A C A T 
' * • * I • I i I I I i I i I » t t i a t t » t t • i • I • 
I • 1 • I I I I I I I I I I I I i I • • i i t I I I I I I I 
numret A A A A A T G A T G A G T T C A T G T C C T T T - G T A - G G G A C A T G G A T G A A A T T G G A A A C C A T C A T T C 
l o 8 2 4 0 163250 168260 168270 168280 168290 
numret T C A G T A A A C T A T C G C A A G A A C A A A A A A C C A A A C A C C G C A T A T T C T C A C T C A T A G G T G G G A 
168300 168310 168320 168330 168340 168350 
J b _ D r : h u m v c a m a 
LOCUS HUMVCAMA 2396 bp ONA PR I 1 4 - J A H - 1 9 9 5 
D E F I N I T I O N Human v a s c u l a r c e l t a d h e s i o n m o l e c u l e - 1 CVCArtl) g e n e , exon 1 . 
A C C E S S I O N M92431 
KEYWORDS v a s c u l a r c e l l a d h e s i o n m o l e c u l e - 1 . 
SOURCE Homo s a p i e n s DNA. 
ORGANISM Homo s a p i e n s . . . 
SCORES I n i t l : 62 I n i t n : 138 O p t : 92 
6 1 . 5 ' i i d e n t i t y i n 117 bp o v e r l a p 
Vu 2 0 3 0 4 0 5 0 
ir GATCATTTTGAAAT CTTTGACCTTTATATTTTAATGAATAAA-ATA TTAGTA 
• I I I I I I I I 1 I t I I I t i l • I I I 
• I I I I I I I I • I I I I I I I I • I t I 
numvca CAAAAAGTTGAT6TT TGTTGCTAAAAGAACTATT TTTATOAATAAATATAAAACTAAGAA 
1610 1620 1630 1640 1650 1660 
60 70 80 90 100 
ir G T T A T - T A G T — A T A A A A T A A T T T A T G T C T T T T G G A C T T A G C A T C C A G T A T T T C T T T T - -
* • • * • I * I I I I 1 1 * 1 1 I I i l l I I I I I I I I I 
I I I I I * • I I I I 1 1 * 1 1 I I I I I I I I I • I I I I 
numvca GTTATGGTGTCCCTTTTT TAAAAAATGACTCATCAA—AAGAAATAACTTTTTCCTTTCT 
1670 1680 1690 1700 1710 
110 120 130 140 150 160 
ir "TTAATAAAGAAAATAATTATTCTCTTGCAATATACTGTGTTTACCTGGGTTTTGAAAAG 
» • t I I I I I I l l l f l 1 1 1 1 * 1 
I I I I I I I l l l l l I I I I I I 
numvca C T TGTAAGAGAAAAA AAT TAATCTCTTTTAGAATTGCAAACATATTTCCTTGATGGAGAA 
1720 1730 1740 1750 1760 1770 
NTG+8 
9i I 
1 J u 
j b _ p r : n u m t k r a 
L ' J C U 3 . H U M T K R A 1 3 5 0 0 bp D N A P H I 
o c F I I T I U N Human t h y m i d i n e k i n a s e g e n e , c o m p l e t e c d s / w i t h 
r e p e a t s in the i n t r o n s . 
A C C E S S I O N M 1 5 2 0 5 M 1 5 2 0 6 
JC'it.rjROS A l u r e p e a t ; r e p e a t r e g i o n ; t n y m i d i n e k i n a s e . 
SOURC£ Human OfIA ( l i b r a r y of Y . - F . L a u ) , c l o n e l a m b d a - t k 4 6 
1 A - J A N - 1 9 9 5 
c l u s t e r e d A l u 
C 1 3 . 
S C O R E S I n i t l : 4 b i n i t n : 573 O p t : 594 
73'%'-' i d e n t i t y i n 240 op o v e r l a p 
l u 20 30 
i 3 u GATCAGTTGA6GGCAGCAGTTCGAGACCAA 
t i l l * t . i . i . I f f I I I ! I • I I I I I 
I I I I I 1 ( 1 1 * 1 I I I l i l t I I I I I I • 
ii unit kr TCCCAGCAC T T 1GGA AG6CC T AGGC G'3 GCGGA R AC T rGAGG TC AGO AG IT TGAGAC C A G 
9 3 8 0 93<?C 9*00 9410 9+20 9430 
AO 50 6u 7J 80 90 
L 3 u C C T 6<3 A C A A C \~TGCJ GAT* C C C C A T C T G T A C T G A - J G A A T A C A A A A T T A A G T C A G G C G T G G 
! ! i ! I 1 ! i ! ! ! : I ! I • • » * * • • • » • • t • . t * • i • i « i i i » * • • • i i i i t i 
• • * * » I I I I I I I I I I I I I I I I I I I » • i i i i i i i i t i i i • • i t I I I I I I I * 
.iu at <r C C A C G C C A A C A T G C T G A A A C C C C A T C T C T A C 1 - A A A P A T A C A A A A A T U G C C A A G C G T O G 
9fiO 9450 qtfSQ 9<,70 94.80 9490 
1 0 0 1 1 0 1 2 0 1 3 0 1 4 0 1 5 0 
i 3u T G G T G C A C G C C T G T A A T C C C A G C T A C : T C 6 G G A < J G C T 6 A 6 I > C A C A A < J * A T ( ? A C T T G A A C C C 
1 ! ! 1 1 1 l l t l l l l ! ! ! ! ! • • • » • • » > • i t i i t t i i i i i i i i i i t i t i i 
nu.nt » r T G 3C AC AC ACC I G T A A X T C C AGC T A C T TGGG A G G C AGAGGC A C A A G A A T TGCT TGAACCT 
9500 9510 9520 9535 9540 9550 
1*0 170 180 190 200 210 
L3u C A G A G G A AGAAGTTGCAGG6AGCCAAC T T f G M C C A C T G r A C T T C A G G C TGGGTGACAGA 
I I ! ; 1 ! ! i ! i I ! ! * * » I I I » * i • • • i » • . * i • • • * 1 I I I * • i • i » • < 
• » » • I I I i i i i i i i i * * * i * * I I i i i i • i i * I I I I * i i • i * i i t • i • 
.iu,nt A r GGGAGGCAGAGuTTGCAGTGAGCCAAGATTA I G C C A C T G C A CT C C AGCC T GGATG AC A G A 
9560 V57C 9580 9590 9600 9610 
220 230 240 250 250 270 
I 3 u ACGACACTATAAATAATA A T A C T A T G A T A A T A T A C C A G A G A G A A C G A A A A A C T G A G T T A A 
: : : : : : : : : : : : :s :: 
nurnt kr G C G A G A C 1 C T G T C I C A A A A A A A A I A G A C A A A G C C A o G C G C A G T G G C T C A T G C C T G T A A T C 
9620 9630 9640 9650 9660 9670 
NTG+13 
92 
1 5 u / r e v 
j o _ o r : h s h w2 
L O C U i HSMW2 £2677 bp L'NA P R I 12-MAY-1995 
D E F I N I T I O N Human DNA sequence f r o m c o s m i d HW2, H u n t i n g t o n ' s D i s e a s e R e g i o n 
chromosome 4 p l 6 . 3 = 
A C C F S S I U N 7.49250 
KEYWORDS 4 p l 6 . 3 ; CpG i s l a n d ; h e l i x - l o o p - h e I i » ; t r a n s c r i p t i o n r e p r e s s o r . 
SOUJCz riuwan. . . . 
S C i H c S I n i t l : 506* I n i t n : 506 O p t : 
79 .4 / . i d e n t i t y i n 218 bp o v e r l a p 
54 7 
239 229 219 209 199 189 
i 5 J C T G G T A T A T T A T C A T AGT AT TAT TA TT 1 A l A G T G T CGTT C T 6 T C A C C C A G C C T G AAGTA C 
t ' t i i • i i i ( i « * i • * • : 
« • • i • I I I I I I i i i i i i i i 
. i srw2 GCT T T T T T T T T T T I f r T r T T T r TfjAGA CGG *GT"C TTGC T C T G T C G C C C A G G C T A G A G T G C 
9570 9580 9590 9600 9610 9620 
J.3u 
i s .i A 2 
1 ? 9 169 159 149 139 _129 
AGTGGTACAAAGT TGGCTCCC IGCAAC T TCTTCCTCTSGGGrrCAAGTC ATTC I TG i <?CC 
I I I I I 
A G T G G C G T G A T C T C G G C T C A C T G C A A C C T C C A C C TCCT6GGT T C A A A C G A T T C TCCT6C C 
9650 ?<S40 9650 9<550 9670 9630 
119 109 99 89 79 69 
13u T C A G C C R C C G A G I A G C T C G G A T T A C A G G C G T G C A C C A C C A C G C C 1 G A C T T A A T T T T G T A 
i • i i i i i « t i i i i • i t > i i i t t i i i i i i i i i i t i i i i . i i i a • • j • ' ' ' * ! * 
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